# Patent

## Title
Vaccine composition for prophylaxis and/or therapy of Alzheimer's disease

## Abstract

A vaccine composition for prophylaxis and/or therapy of Alzheimer's disease, which comprises a fusion protein prepared by inserting a single or tandemly repeated multiple copies of amyloid β antigenic peptide having 5 to 15 continuous amino acid residues derived from the N-terminus of amyloid β peptide into a wild type seed storage protein.

## Background
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of U.S. application Ser. No. 13/130,465, filed May 20, 2011 which is the U.S. National Phase under 35 U.S.C. §371 of International Application PCT/JP2009/069977, filed Nov. 26, 2009, which was published in a non-English language, which claims priority to JP Patent Application No. 2008-304006, filed Nov. 28, 2008.


REFERENCE TO SEQUENCE LISTING, TABLE, OR COMPUTER PROGRAM LISTING
This application includes a sequence listing.
TECHNICAL FIELD
The present invention relates to a vaccine composition for prophylaxis and/or therapy of Alzheimer's disease and a method of prophylaxis and/or therapy of Alzheimer's disease using the vaccine composition.
BACKGROUND ART
Alzheimer's disease is a neurodegenerative disease caused by accumulation of a causative substance such as β-amyloid in brain, causing damage to nerve cells. Although the number of patients suffering from Alzheimer's disease is expected to increase upon the advent of an aging society, prophylactic agents and therapeutic agents for the disease are hardly available, and development of new prophylactic agents, therapeutic agents, vaccines and the like has been demanded.
The major amyloid β proteins produced in the brain of Alzheimer's disease patients are composed of 40 to 43 amino acids produced by cleavage of amyloid precursor protein with γ-secretase. Amyloid plaques are aggregates constituted by amyloid β and surrounding microglia, fibrous astroglia and dystrophic neurites. The most commonly accepted hypothesis at present on the pathology of Alzheimer's disease is the “amyloid cascade hypothesis”, in which formation of amyloid plaques due to aggregation and deposition of amyloid β is considered to be the cause. Based on this hypothesis, the vaccine immunotherapy is drawing attention as a novel therapeutic method for Alzheimer's disease. The vaccine immunotherapy is a method to remove amyloid β in the brain by an immunological method, and it has been reported that intramuscular administration of amyloid β42 to disease model transgenic mice together with an adjuvant caused decrease in the amount of deposition of amyloid in the brain (WO 99/27944; Schenk D. et al, Nature 400:173-177, 1999).
Further, although an anti-amyloid β antibody that recognizes amyloid has been detected in the serum of a subject to whom a synthetic amyloid β42 was intramuscularly administered together with an adjuvant, side effects such as meningoencephalitis have been problematic in clinical trials (Hock C. et al., Nat. Med. 8:1270-1275, 2002).
Therefore, vaccine compositions for prophylaxis and/or therapy of Alzheimer's disease, which are free from side effects, are demanded.
DISCLOSURE OF THE INVENTION
The present invention aims to provide a novel composition for prophylaxis and/or therapy of Alzheimer's disease and a method of prophylaxis and/or therapy of Alzheimer's disease using the vaccine composition.
The present inventors intensively studied to solve the above problems and succeeded in discovering that Alzheimer's disease can be prevented and treated by using a vaccine composition comprising a fusion protein prepared by inserting a single or tandemly repeated multiple copies of amyloid β antigenic peptide having 5 to 15 continuous amino acid residues derived from the N-terminus of amyloid β peptide into a seed storage protein, thereby completed the present invention.
That is, the present invention provides:

    [1] A vaccine composition for prophylaxis and/or therapy of Alzheimer's disease, which comprises a fusion protein prepared by inserting a single or tandemly repeated multiple copies of amyloid β antigenic peptide having 5 to 15 continuous amino acid residues derived from the N-terminus of amyloid β peptide into a wild type seed storage protein.
    [2] The vaccine composition according to [1], wherein said seed storage protein is selected from the group consisting of A1aB1b subunit of soybean 11S globulin, common bean arcelin, and rice prolamin.
    [3] The vaccine composition according to [1], wherein said vaccine composition induces production of amyloid-specific antibodies in the animal given said vaccine composition.
    [4] The vaccine composition according to [2], wherein said vaccine composition induces production of amyloid-specific antibodies in the animal given said vaccine composition.
    [5] The vaccine composition according to [1], wherein said vaccine composition decreases in soluble and/or insoluble amyloid β1 to 42 involved in amyloid plaques in the brain of the animal suffering from Alzheimer's disease by the administration of said vaccine composition to said animal.
    [6] The vaccine composition according to [2], wherein said vaccine composition decreases in soluble and/or insoluble amyloid β1 to 42 involved in amyloid plaques in the brain of the animal suffering from Alzheimer's disease by the administration of said vaccine composition to said animal.
    [7] The vaccine composition according to [1], wherein said vaccine composition induces recovery of cognitive abilities in said animal.
    [8] The vaccine composition according to [2], wherein said vaccine composition induces recovery of cognitive abilities in said animal. [9] A method for preventing and/or treating Alzheimer's disease, said method comprising the step of administering a vaccine composition to an animal which has the amyloid plaques in its brain, wherein said vaccine composition comprises a fusion protein prepared by inserting a single or tandemly repeated multiple copies of amyloid antigenic peptide having 5 to 15 continuous amino acid residues derived from the N-terminus of amyloid β peptide into a wild type seed storage protein.
    [10] The method according to [9], wherein a single copy or tandemly repeated 2 to 5 copies of said amyloid β antigenic peptide is inserted into said wild type seed storage protein.





BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a schematic diagram showing the amino acid sequences encoded by the variable regions in the amino acid sequence of the A1aB 1b subunit of soybean glycinin (SEQ ID NO: 2).
FIG. 2 is a diagram showing the construction procedure for a plasmid pUHGA1aB1bM.
FIG. 3 is a schematic diagram showing the structure of the plasmid pUHG which was used for incorporation of a gene encoding a modified seed storage protein. The gene of an arbitrary modified seed storage protein is inserted into the SmaI site.
FIG. 4 shows photographs showing detection of accumulation of a β-amyloid antigenic determinant in seeds of a transformed soybean to which a gene encoding a modified A1aB1M1 was introduced, which detection was carried out by Western blotting. The samples in the respective lanes are as follows. 1: Transformed soybean 10-2 No. 1 produced by introducing A1aB1M1 to variety Jack; 2: transformed soybean 10-2 No. 2 produced by introducing A1aB1M1 to variety Jack; 3: transformed soybean 10-2 No. 3 produced by introducing A1aB1M1 to variety Jack; 4: variety Jack (control); 5: transformed soybean 16-2 No. 1 produced by introducing A1aB1M1 to a storage protein-deficient line; 6: transformed soybean 16-2 No. 2 produced by introducing A1aB1M1 to a storage protein-deficient line; 7: transformed soybean 16-2 No. 3 produced by introducing A1aB1M1 to a storage protein-deficient line; and 8: a storage protein-deficient line (control).
FIG. 5 shows photographs showing detection of accumulation of a β-amyloid antigenic determinant in seeds of a transformed soybean to which a gene encoding modified arcelin (Arc5M1) was introduced, which detection was carried out by Western blotting. The samples in the respective lanes are as follows. 1: Transformed soybean 2-1 No. 1 produced by introducing Arc5M1 to variety Jack; 2: transformed soybean 2-1 No. 2 produced by introducing Arc5M1 to variety Jack; 3: transformed soybean 2-2 No. 1 produced by introducing Arc5M1 to variety Jack; and 4: transformed soybean 2-2 No. 2 produced by introducing Arc5M1 to variety Jack.
FIG. 6 shows a photograph showing detection of accumulation of a β-amyloid antigenic determinant in seeds of a transformed soybean to which a gene encoding modified prolamin (PR10M1) was introduced, which detection was carried out by Western blotting. The samples in the respective lanes are as follows. 1: Transformed soybean 1-1 No. 1 produced by introducing PR10M1 to variety Jack; 2: transformed soybean 1-1 No. 2 produced by introducing PR10M1 to variety Jack; 3: transformed soybean 4-2 No. 1 produced by introducing PR10M1 to variety Jack; and 4: transformed soybean 4-2 No. 2 produced by introducing PR10M1 to variety Jack.
FIG. 7 shows photographs showing detection of accumulation of a β-amyloid antigenic determinant in seeds of a transformed soybean to which a gene encoding modified A1aB1M1 or A2PA1aB1bM3 was introduced, which detection was carried out by Western blotting. The samples in the respective lanes are as follows. 1: transformed soybean line 4-6 produced by introducing A2PA1aB1bM1 to a storage protein-deficient line; 2: transformed soybean line 7-1 produced by introducing A1aB1bM1 to a storage protein-deficient line; 3: transformed soybean line 8-1 No. 1 produced by introducing A1aB1bM1 to variety Jack; 4: transformed soybean line 8-1 No. 2 produced by introducing A1aB1bM1 to variety Jack; 5: storage protein-deficient line; 6: transformed soybean line 3-1 No. 1 produced by introducing A2PA1aB1bM3 to a storage protein-deficient line; and 7: transformed soybean line 3-1 No. 2 produced by introducing A2PA1aB1bM3 to a storage protein-deficient line.
FIG. 8 shows a diagram (photographs) showing the results of a stability assay of Aβ4-10 (the peptide having the amino acid sequence shown in SEQ ID NO:3) in seeds of the transformed soybean A1aB1bM3. The samples in the respective lanes are as follows. A-1, A-2: heat-untreated group; B-1, B-2: roasted group; C-1, C-2: water-boiled group; D-1, D-2: heat-treated extract group.
FIG. 9 shows a diagram (photographs) showing evaluation of the relationship between the repeat number of Aβ4-10 and the antibody titer. The samples in the respective lanes are as follows. 1: Reaction group in which purified antibody key-limpet-hemocyanin(KLH)-P1 was allowed to react with substrate Aβ42 (400 picomoles); 2: reaction group in which purified antibody KLH-P1 was allowed to react with substrate Aβ42 (1000 picomoles); 3: reaction group in which purified antibody KLH-P2 was allowed to react with substrate Aβ42 (400 picomoles); 4: reaction group in which purified antibody KLH-P2 was allowed to react with substrate Aβ42 (1000 picomoles); 5: reaction group in which purified antibody KLH-P3 was allowed to react with substrate Aβ42 (400 picomoles); and 6: reaction group in which purified antibody KLH-P3 was allowed to react with substrate Aβ42 (1000 picomoles).
FIG. 10 shows the measurement result of the anti-amyloid β antibody titer in the mouse serum after administration of the vaccine compositions.
FIG. 11 shows the memory disorder-ameliorating effect evaluated by the water maze test.
FIG. 12 shows the amount of accumulation of amyloid in brain of the mouse administered with the vaccine composition.



DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention will now be described in detail.
1. Gene Encoding Wild-Type Seed Storage Protein
In the present invention, the “wild-type seed storage protein” means a seed storage protein before inserting the Alzheimer's disease vaccine. Examples of the wild-type seed storage protein in the present invention include the respective subunits constituting soybean 11S globulin, the respective subunits constituting soybean 7S globulin, arcelin in common bean, prolamin in rice, globulin in rice, and further, seed storage proteins in other crops. Preferred examples of the wild-type seed storage protein include the A1aB1b subunit of 11S globulin and the α subunit and β subunit of 7S globulin in soybean, among which the A1aB1b subunit of 11S globulin in soybean is more preferred.
Further, examples of the wild-type seed storage protein in the present invention include proteins containing the amino acid sequences shown in SEQ ID NO:2, SEQ ID NO:37 and SEQ ID NO:45, and proteins containing amino acid sequences having identities of not less than 80%, preferably not less than 90%, more preferably not less than 95% to these amino acid sequences. Among them, A1aB1b subunit of 11S globulin in soybean containing the amino acid sequence having identity of not less than 80%, preferably not less than 90%, more preferably not less than 95% to SEQ ID NO:2 is more preferred. The wild-type seed storage protein in the present invention also include proteins containing the amino acid sequences shown in SEQ ID NO:2, SEQ ID NO:37 and SEQ ID NO:45 except that one or more (preferably 1 to 20, 1 to 10, or 1 to 5) amino acids are substituted, inserted, added and/or deleted as long as the function of the seed storage protein is maintained.
Here, the identity (%) between amino acid sequences means the maximum identity (%) between the amino acid sequences which is obtained by aligning the two amino acid sequences to be compared while introducing, as required, gaps thereto (alignment). The alignment for the purpose of determining the identity between amino acid sequences can be carried out using various methods which are well-known to those skilled in the art. For example, publicly available computer software such as BLAST, BLAST-2, ALIGN and Megalign (DNASTAR) software and commercially available software such as Gene Works 2.5.1 software (Teijin System Technology, Inc.) and GENETIX-WIN (Software Development Co., Ltd) may be used.
Examples of the gene encoding a wild-type seed storage protein in the present invention include genes encoding the respective subunits constituting soybean 11S globulin, genes encoding the respective subunits constituting soybean 7S globulin, a gene encoding arcelin in common bean, a gene encoding prolamin in rice, a gene encoding globulin in rice, and further, genes encoding seed storage proteins in other crops. Preferred examples of the gene include a gene encoding the A1aB1b subunit of 11S globulin and genes encoding the α subunit and β subunit of 7S globulin in soybean, among which a gene encoding the A1aB1b subunit of 11S globulin in soybean is more preferred.
Further, examples of the gene encoding a wild-type seed storage protein in the present invention include genes containing the nucleotide sequences shown in SEQ ID NO:1, SEQ ID NO:36 and SEQ ID NO:44, and genes containing nucleotide sequences having identities of not less than 80%, preferably not less than 90%, more preferably not less than 95% to these nucleotide sequences. Among them, a gene encoding A1aB1b subunit of 11S globulin in soybean containing the nucleotide sequence having identity of not less than 80%, preferably not less than 90%, more preferably not less than 95% to SEQ ID NO:1 is more preferred.
Here, the identity (%) between nucleotide sequences means the maximum identity (%) between the nucleotide sequences which is obtained by aligning the two nucleotide sequences to be compared while introducing, as required, gaps thereto (alignment). The alignment for the purpose of determining the identity between nucleotide sequences can be carried out using various methods which are well-known to those skilled in the art. For example, publicly available computer software such as BLAST, BLAST-2, ALIGN and Megalign (DNASTAR) software and commercially available software such as Gene Works 2.5.1 software (Teijin System Technology, Inc.) and GENETIX-WIN (Software Development Co., Ltd) may be used.
Examples of the gene encoding a wild-type seed storage protein in the present invention also include genes which hybridize with a DNA containing the nucleotide sequence complementary to SEQ ID NO:1, SEQ ID NO:36 and SEQ ID NO:44 under stringent conditions wherein washing is performed at a salt concentration of 0.1×SSC, 0.1% SDS at 68° C.
2. Gene Encoding Modified Seed Storage Protein
The vaccine composition of the present invention comprises a modified seed storage protein, that is, a fusion protein prepared by inserting an Alzheimer's disease vaccine composed of a single or tandemly repeated multiple copies of amyloid antigenic peptide having 5 to 15 continuous amino acid residues derived from the N-terminus of amyloid β peptide into a wild type seed storage protein.
The gene encoding a modified seed storage protein in the present invention can be produced by inserting a gene encoding the Alzheimer's disease vaccine to a variable region(s) of a gene encoding a wild-type seed storage protein such that frameshift does not occur.
Here, “inserting a gene encoding the Alzheimer's disease vaccine such that frameshift does not occur” means that the gene encoding the Alzheimer's disease vaccine has been inserted to a variable region(s) of a gene encoding a wild-type seed storage protein such that the amino acid sequence of the modified seed storage protein excluding the amino acid sequence of the Alzheimer's disease vaccine is identical to the amino acid sequence of the corresponding wild-type seed storage protein.
Further, “inserting a gene encoding an Alzheimer's disease vaccine” means that the gene encoding an Alzheimer's disease vaccine has been inserted without causing deletion of a nucleotide sequence encoding the variable region(s), as well as that all or a part of the nucleotide sequence encoding the variable region(s) was substituted with the gene encoding an Alzheimer's disease vaccine.
In the present invention, a variable region of a gene encoding a wild-type seed storage protein means a region which allows, even when an exogenous gene has been inserted thereto such that frameshift does not occur, the protein expressed from the resulting gene to maintain a stable spatial structure equivalent to that of the wild-type seed storage protein, thereby allowing maintenance of the properties of the wild-type seed storage protein.
For example, when the gene encoding a wild-type seed storage protein is the gene encoding the A1aB1b subunit of soybean 11S globulin containing the amino acid sequence of SEQ ID NO:2, five portions including the region encoding amino acid positions 20-28 (variable region I), the region encoding amino acid positions 111-128 (variable region II), the region encoding amino acid positions 198-216 (variable region III), the region encoding amino acid positions 268-315 (variable region IV) and the region encoding amino acid positions 490-495 (variable region V) in SEQ ID NO:2 are known as variable regions (FIG. 1).
Further, when the gene encoding a wild-type seed storage protein is a gene containing a nucleotide sequence encoding an amino acid sequence which has a certain identity to the amino acid sequence shown in SEQ ID NO:2, that is, the amino acid sequence shown in SEQ ID NO:2 except that one or more amino acids are substituted, inserted, added and/or deleted, the variable regions are the region encoding the amino acid sequence corresponding to amino acid positions 20-28, the region encoding the amino acid sequence corresponding to amino acid positions 111-128, the region encoding the amino acid sequence corresponding to amino acid positions 198-216, the region encoding the amino acid sequence corresponding to amino acid positions 268-315 and the region encoding the amino acid sequence corresponding to amino acid positions 490-495.
Here, when two amino acid sequences to be compared are aligned with each other to attain the maximum identity (%) between the amino acid sequences while introducing gaps as required, the “amino acid sequence corresponding to” a particular amino acid sequence means a partial amino acid sequence that corresponds to the other particular partial amino acid sequence. Such an amino acid sequence can be easily specified by those skilled in the art.
When plural variable regions exist in the gene encoding a wild-type seed storage protein, the gene encoding a modified seed storage protein can be prepared by inserting a gene encoding an Alzheimer's disease vaccine to one or more of the variable regions.
For example, when a gene encoding the A1aB1b subunit of soybean 11S globulin containing the amino acid sequence of SEQ ID NO:2 is used as the gene encoding a wild-type seed storage protein, any one of the variable regions II, III, IV and V may be selected as the variable region to which the gene encoding an Alzheimer's disease vaccine is to be inserted, and the gene encoding an Alzheimer's disease vaccine is more preferably inserted to the variable region III. Further, as the variable regions to which the gene encoding an Alzheimer's disease vaccine is to be inserted, two or more regions among the variable regions II, III, IV and V may be selected, and, for example, insertion into the three regions II, III and IV at the same time, insertion into the four regions II, III, IV and V at the same time, and the like can be carried out. Here, introduction of the gene encoding an Alzheimer's disease vaccine needs to be carried out such that frameshift does not occur in the nucleotide sequence encoding the wild-type seed storage protein.
Further, when a gene encoding common bean arcelin 5 containing the amino acid sequence shown in SEQ ID NO:37 is used as the gene encoding a wild-type seed storage protein, since the variable region(s) of the gene is/are not known, it is necessary to compare its DNA sequence with that of the A1aB1b subunit to confirm disordered regions, and to compare its amino acid sequence and spatial structure with those of other similar storage proteins to confirm the differences in the gaps of the sequence and the structural differences, thereby assuming the variable region(s). It is preferred to insert the gene encoding an Alzheimer's disease vaccine into the region encoding amino acid positions 149-150 (variable region A) and/or the region encoding amino acid positions 250-251 (variable region B) in SEQ ID NO:37, which regions can be specified by such assumption.
Further, when the gene encoding the wild-type seed storage protein contains a nucleotide sequence encoding an amino acid which has a certain identity to the amino acid sequence shown in SEQ ID NO:37, that is, the amino acid sequence shown in SEQ ID NO:37 except that one or more amino acids are substituted, inserted, added and/or deleted, the gene encoding an Alzheimer's disease vaccine is preferably inserted into the region encoding the amino acid sequence corresponding to amino acid positions 149-150, the region encoding the amino acid sequence corresponding to amino acid positions 250-251 in SEQ ID NO:37.
Further, when a gene encoding rice prolamin containing the amino acid sequence shown in SEQ ID NO:45 is used as the gene encoding a wild-type seed storage protein, since the spatial structure and the variable region(s) of the gene are not known, it is necessary to compare its amino acid sequence with those of other similar storage proteins to confirm the gap structure, thereby assuming the variable region(s). It is preferred to insert the gene encoding an Alzheimer's disease vaccine into the region encoding amino acid positions 110-111 (variable region a) in SEQ ID NO:45, which region can be specified by such assumption.
Further, when the gene encoding the wild-type seed storage protein contains a nucleotide sequence encoding an amino acid which has a certain identity to the amino acid sequence shown in SEQ ID NO:45, that is, the amino acid sequence shown in SEQ ID NO:45 except that one or more amino acids are substituted, inserted, added and/or deleted, the gene encoding an Alzheimer's disease vaccine is preferably inserted into the region encoding the amino acid sequence corresponding to amino acid positions 110-111 in SEQ ID NO:45.
3. Gene Encoding the Amyloid β Antigenic Peptide
The gene encoding the Alzheimer's disease vaccine in the present invention is a DNA encoding a single or tandemly repeated multiple copies of β-amyloid antigenic peptide composed of 5 to 15, preferably 5 to 10 continuous amino acid residues derived from the N-terminus of the naturally occurring amyloid β peptide (42 amino acid residues). More particularly, a peptide consisting of the 1st to 15th amino acids from the N-terminus of SEQ ID NO:62 may be used, and a peptide of a consisting of the 1st to 5th amino acids (SEQ ID NO:63) or 4th to 10th amino acids (SEQ ID NO:3) is preferably used.
Since a nucleotide sequence encoding β-amyloid is known (GenBank accession No. AB113349), it is possible to isolate a DNA encoding β-amyloid or a β-amyloid antigenic determinant from a cDNA library, by a screening operation based on this nucleotide sequence information. A DNA encoding a β-amyloid antigenic determinant can be prepared also by chemical synthesis.
Further, in the present invention, the Alzheimer's disease vaccine can also be inserted to a variable region(s) of a gene encoding a seed storage protein in such a manner that plural genes encoding the vaccine are tandemly linked to each other, thereby allowing expression of the vaccine. For example, the gene encoding a β-amyloid antigenic determinant may be inserted, such that frameshift does not occur, to a variable region(s) in such a manner that an integer number of 1 to 20, preferably an integer number of 2 to 15, more preferably an integer number of 2 to 5, especially preferably 2 copies of the gene are linked to each other.
Further, when the gene encoding the Alzheimer's disease vaccine is inserted into the gene encoding a wild-type seed storage protein, a nucleotide sequence(s) which encode(s) a sequence recognized by a protease may also be added to the 5′-end and/or the 3′-end of the gene encoding an Alzheimer's disease vaccine. Thus, the Alzheimer's disease vaccine can be cleaved out with the protease from the modified seed storage protein produced in seeds. Examples of such a protease include thermolysin.
4. Production of Vaccine Composition Comprising a Modified Seed Storage Protein in which amyloid β Antigenic Peptide is Inserted
The method for producing the vaccine composition of the present invention is not restricted, and the vaccine composition comprising the modified seed storage protein may be prepared by a conventional peptide synthesis method or by linking peptides which have been synthesized in advance by a conventional peptide synthesis method. Further, the protein may be synthesized using a peptide synthesizer commercially available from various manufacturers, according to the manufacturer's instructions attached to the apparatuses.
Further, the fusion protein (modified seed storage protein) of the present invention may be prepared by a recombinant DNA technology. For example, DNA encoding the amino acid sequence of the designed protein is prepared by using PCR, restriction endonuclease etc, and the DNA is inserted into an autonomously replicable vector containing a promoter functioning in the host, followed by introducing the resulting vector to a host such a microorganism as E. coli, Bacillus subtilis, actinomycetes or yeast; or animal or plant, or cells or tissues thereof; thereby preparing a transformant or a transgenic animal or plant. This is then cultured or grown, and the fusion protein of the present invention may then be recovered and purified therefrom by an appropriate method.
The fusion protein of the present invention may be produced using a recombinant plant. Examples of the plant species include those belonging to Asteraceae, Brassicaceae, Cucurbitaceae, Apiaceae, Rosaceae, Vitaceae, Vaccinium, Caricaceae, Fabaceae, Juglandaceae, Chenopodiaceae, Solanaceae, Convolvulaceae, Poaceae, Dioscoreaceae, Convolvulaceae and the like. More particular examples of the plant species include lettuce, chicory, Artemisia, broccoli, cabbage, radish, Japanese horse radish, mustard, cucumber, melon, pumpkin, Sechium edule, carrot, honewort, celery, apple, plum, Japanese apricot, peach, strawberry, raspberry, almond, pear, loquat, grape, cranberry, cowberry, blueberry, papaya, alfalfa, soybean, walnut, spinach, tomato, capsicum, sweet potato, rice, maize, wheat, barley, rye, yam and potato.
Especially when the fusion protein is produced by a recombinant plant, a plant body such as seeds, stems and leaves, fruits, tubers or the like may be processed as it is, to be used as a composition for oral ingestion, which contains the fusion protein of the present invention.
Hereinafter, embodiments using a soybean as a host are shown, but the present invention is not limited to these embodiments.
4. Vector for Gene Transfer
The vector for gene transfer may have a structure wherein a promoter that induces soybean seed-specific expression is linked to the upstream of the gene. Further, a terminator may also be linked to the downstream of the gene.
Examples of the promoter that induces soybean seed-specific expression include the soybean 11S globulin promoter and the common bean arcelin promoter, and examples of the terminator include the soybean 11S globulin terminator, the common bean arcelin 2 terminator, the 35S terminator and the NOS terminator of cauliflower mosaic virus.
Examples of the soybean 11S globulin promoter include the promoter of the soybean 11S globulin A1aB1b subunit having the sequence shown in SEQ ID NO:18, and the soybean 11S globulin promoter may be one having an identity of not less than 95% to this sequence as long as it has a seed-specific promoter activity. Examples of the soybean 11S globulin terminator include the terminator of the soybean 11S globulin A1aB1b subunit having the sequence shown in SEQ ID NO:21, and the soybean 11S globulin terminator may be one having an identity of not less than 95% to this sequence as long as it has a seed-specific terminator activity.
Examples of the common bean arcelin promoter include the promoter of common bean arcelin 2 having the sequence of nucleotide positions 1399-3860 in SEQ ID NO:56, and the common bean arcelin promoter may be one having an identity of not less than 95% to this sequence as long as it has a seed-specific promoter activity. Examples of the common bean arcelin terminator include the common bean arcelin 2 terminator having the sequence shown in SEQ ID NO:59, and the common bean arcelin terminator may be one having an identity of not less than 95% to this sequence as long as it has a seed-specific terminator activity.
To the vector of the present invention, a selection marker gene for selecting recombinants, and a reporter gene for confirming expression of the introduced gene may be inserted. Examples of the selection marker gene include the hygromycin resistance gene, the phosphinothricin resistance gene or the like, and examples of the reporter gene include the β-glucuronidase (GUS) gene, chloramphenicol acetyltransferase (CAT) gene, luciferase (LUC) gene and GFP gene or the like.
The vector of the present invention may be obtained also by inserting a DNA fragment, which contains a promoter for induction of seed-specific expression, a gene encoding a modified storage protein linked to the downstream of the promoter, and a terminator linked to the further downstream, to a vector comprising the above-described selection marker gene and/or reporter gene.
5. Soybean Plant which can be Transformed
Examples of the soybean which can be transformed in the present invention include varieties which are generally used for food, for feed or for producing oil. The soybean to be transformed is preferably partially or totally deficient for the endogenous seed storage proteins, and examples of the soybean include those which are partially or totally deficient for soybean 11S globulin and/or soybean 7S globulin. Here, “partially deficient” means cases where the expression level is lower than in the wild type, as well as cases where only a part of the subunits are completely deficient, and cases where the expression levels of only a part of the subunits are lower than those in the wild type. Particular examples of the soybean include the mutant line EnB1, which is deficient for soybean 11S globulin, the mutant line QY2, which is deficient for soybean 7S globulin, and the mutant line QF2, which is deficient for both 11S globulin and 7S globulin. Further examples of the soybean include progeny lines derived by hybridization between such defective lines and common varieties (e.g., Jack or the like).
Confirmation of the fact that the soybean is partially or totally deficient for endogenous soybean 11S globulin and/or soybean 7S globulin can be carried out by electrophoresis of the storage proteins prepared from seeds.
6. Preparation of Transformed Soybean Plant
Examples of the material which may be used for preparation of the transformed soybean plant include plant tissues such as roots, stems, leaves, seeds, embryos, ovules, ovaries, shoot apices, anther and pollens, and sections thereof; and plant cultured cells such as undifferentiated calluses, adventive embryos and protoplasts or the like.
The introduction of the gene encoding a modified seed storage protein to the above material may be carried out by various methods which have already been reported and established, and it is preferred to introduce the above-mentioned vector for gene transfer using the Agrobacterium method, PEG method, electroporation method, particle gun method, whisker ultrasonic method or the like.
Using the resistance effect given by the selection marker gene as an index, cells of the transformed soybean plant can be selected from the material to which the gene encoding a modified seed storage protein has been introduced. From the selected cells, a transformed soybean plant body can be obtained through the step of regenerating a plant body, which step has been reported for each plant species.
By cultivating the thus obtained transformed soybean plant body to allow seed ripening, seeds of the transformed soybean of the present invention can be obtained, and the Alzheimer's disease vaccine of interest can be obtained in the transformed seeds.
Whether or not the gene encoding the Alzheimer's disease vaccine has been introduced into the plant body can be confirmed by the PCR method, Southern hybridization method, Northern hybridization method, Western blotting method or the like. For example, by extracting protein from seeds of the transformed soybean plant body and carrying out Western blotting by immunostaining using a primary antibody specific to the Alzheimer's disease vaccine and a secondary antibody labeled with horseradish peroxidase (HRP) or the like, it is possible to confirm appropriate introduction of the gene encoding the Alzheimer's disease vaccine, accumulation of the Alzheimer's disease vaccine in the seeds, and the amount of the vaccine accumulated.
The performance of the Alzheimer's disease vaccine contained in the modified seed storage protein accumulated in the seeds of the transformed soybean plant can be evaluated by, for example, using a disease-model mouse that develops Alzheimer's disease. More particularly, the modified seed storage protein containing the Alzheimer's disease vaccine, or the Alzheimer's disease vaccine cleaved out from the modified seed storage protein with a protease followed by purification, is administered to the above model mouse by subcutaneous injection or oral administration. The performance of the Alzheimer's disease vaccine can be evaluated by investigating production of antibodies against the Alzheimer's disease vaccine, the amount of β-amyloid, brain tissue, and/or behavior disorder in the mouse. The modified seed storage protein containing the Alzheimer's disease vaccine, or the Alzheimer's disease vaccine cleaved out from the modified seed storage protein with a protease followed by purification, may be administered as a mixture with an adjuvant.
The Alzheimer's disease vaccine can be produced in a large amount by cultivating and then collecting seeds of the transformed soybean that accumulates a modified seed storage protein containing the vaccine, in the outdoor field, or closed facilities for cultivation where the environment is artificially controlled.
The seeds wherein the modified seed storage protein containing the Alzheimer's disease vaccine is accumulated can be used for prophylaxis and/or therapy of Alzheimer's disease, as a composition containing the Alzheimer's disease vaccine. For example, the seeds processed by pulverization or the like may be made into the form of a tablet, granule, powder, capsule, beverage or the like.
Further, the above composition may contain the modified seed storage protein accumulated in the seeds, which protein has been extracted and purified. For example, after a ground product of the seeds subjected to defatting and heat treatment, the modified seed storage protein containing the Alzheimer's disease vaccine of interest may be purified by an apparatus such as liquid chromatography. Further, the above-described composition may contain the Alzheimer's disease vaccine which has been prepared by treating the modified seed storage protein with a protease and purifying the resulting product, thereby partially or totally removing the part of the wild-type seed storage protein from the modified seed storage protein.
5. Method for Administration of the Vaccine Composition to Animal
By administering the vaccine composition produced as described above to an animal individual, an immune response against amyloid β is induced, causing decrease in deposition of amyloid β.
The vaccine composition of the present invention may be administered through any of the conventional routes, such as subcutaneous, oral, intramuscular, parenteral and enteral routes. Examples of the administration method include oral ingestion; and intracoelomic administration such as subcutaneous, intracutaneous, intramuscular, intravascular, intraperitoneal and intrathoracic administration and the like using an injector, catheter, drip or the like.
Examples of the animal to which the vaccine composition of the present invention is to be administered include mammals such as human and other vertebrates.
When the vaccine composition of the present invention is administered, an adjuvant (a substance that can enhance an immune response against an immunogen, or a composition containing the substance) which is conventionally used for preparation of a vaccine may be blended, and examples of the adjuvant include cholera toxin B and saponins.
The dose of the vaccine composition may be appropriately set depending on the conditions such as the age, sex, body weight, symptoms, administration route and the like of the animal to which the composition is to be administered, and the dose is generally within the range of 0.1 to 3000 μg/kg body weight, preferably within the range of 1 to 1000 μg/kg body weight in terms of the dose of the amyloid β peptide. The above-described dose may be administered at intervals of several days, or several weeks to several months, for example, at intervals of 1 to 12 weeks. The appropriate number of doses is several times to several ten times, but the number of doses is not restricted.
By the method of the present invention, an immune response against amyloid β is induced. The immune response against amyloid β can be confirmed by production of anti-amyloid β antibodies, decrease in the amount of amyloid β in the brain tissue, decrease in the deposition of amyloid β, or the like.
The production of anti-amyloid β antibodies can be investigated by detecting anti-amyloid antibody in the blood. The level of the antibody can be measured by, for example, the ELISA (enzyme-linked immunosorbent assay) method. The ELISA method is carried out, for example, by adsorbing an antigen on a microplate and preparing an antiserum, followed by 2-fold serially diluting the prepared antiserum (1:1000 starting solution) and adding the diluted antiserum to the plate, to cause antigen-antibody reaction. For coloring, the resultant may be reacted with a heterologous antibody as a secondary antibody, which is prepared by labeling an antibody of an immunized animal with the peroxidase enzyme. When the absorbance is 1⁄2 of the maximum coloring absorbance, the antibody titer can be calculated based on the dilution factor of the antibody.
The amyloid β level in the brain tissue can be measured using a brain tissue extract and Biosource ELISA kit, for example.
The effect on reduction of deposition of amyloid β (amyloid plaques) can be measured by, for example, the following method. A brain tissue section is treated with 70% formic acid and endogenous peroxidase is inactivated with 5% H2O2, followed by reacting an anti-Aβ antibody with the section and carrying out DAB staining using a peroxidase-labeled secondary antibody. Thereafter, the area wherein Aβ is accumulated can be measured under the microscope. The level of deposition of amyloid β can be judged to have decreased if the ratio of the area wherein Aβ is accumulated is smaller than in the case wherein the vaccine composition of the present invention is not administered.
The present invention will now be described more concretely by way of Examples, but the present invention is not restricted to these Examples.
The procedures of the experimental methods carried out in the Examples below are those according to “Molecular Cloning” 2nd Ed. (J. Sambrook et al., Cold Spring Harbor Laboratory press, published in 1989) unless otherwise specified.
EXAMPLES
Example 1
Construction of Expression Plasmids for Modified Soybean 11S Globulin A1aB1b
Expression plasmids for expression of genes encoding modified A1aB1b containing the peptide having the amino acid sequence shown in SEQ ID NO:3 (hereinafter abbreviated as Aβ4-10), which is known as a β-amyloid antigenic determinant, in soybean seeds were constructed. The procedure for the construction is shown in FIG. 2.
An oligonucleotide having three copies of a nucleotide sequence encoding Aβ4-10 which are tandemly linked to each other (the sense strand, SEQ ID NO:4) and the oligonucleotide having its complementary sequence (the antisense strand, SEQ ID NO:5) were synthesized using the custom DNA synthesis service by FASMAC Co., Ltd. (the sense strand and the antisense strand are hereinafter referred to as 410F and 410R, respectively). Unless otherwise specified, the hereinafter-mentioned oligonucleotides were those synthesized using the custom DNA synthesis service by the above manufacturer. In the presence of ATP at a final concentration of 1 mM, 100 pmol each of 410F and 410R was subjected to phosphorylation reaction with T4 Polynucleotide Kinase (manufactured by TAKARA BIO INC.), and the reaction solutions after the reaction were mixed together, followed by heating the resulting mixture at 94° C. for 10 minutes and then allowing the mixture to cool gradually to 37° C. for 1 hour, thereby carrying out annealing. By this process, a double-stranded DNA fragment encoding a peptide wherein three copies of Aβ4-10 are tandemly linked to each other ((Aβ4-10)×3) was obtained.
Using, as a template, the plasmid pBSK-A1aB1b (obtained from Kyoto University) wherein cDNA of the known A1aB1b gene (GenBank accession No. AB113349) is cloned at the SmaI site of pBluescript II SK(−) (manufactured by Stratagene), PCR was carried out to amplify a fragment containing the vector portion such that the 5′-end and the 3′-end of the fragment are positioned at a specific variable region of the gene encoding A1aB1b. The obtained DNA fragment was ligated with the double-stranded DNA fragment encoding (Aβ4-10)×3, to prepare the gene encoding a modified A1aB1b. The method is more concretely described below.
A total of five primer sets, that is, the primer set (PS-1) composed of the primer pair of SEQ ID NOs:6 and 7 for insertion into the variable region II, the primer set (PS-2) composed of the primer pair of SEQ ID NOs:8 and 9 for insertion into the variable region III, the primer set (PS-3) composed of the primer pair of SEQ ID NOs:10 and 11 and the primer set (PS-4) composed of the primer pair of SEQ ID NOs:12 and 13 for insertion into the variable region IV, and the primer set (PS-5) composed of the primer pair of SEQ ID NOs:14 and 15 for insertion into the variable region V, of the gene encoding A1aB1b having the sequence shown in SEQ ID NO:1 were prepared. The primers were synthesized such that nucleotide substitutions for introducing amino acid substitutions in the immediate downstream of the insertion regions were introduced in order to allow cleaving out of (Aβ4-10)×3 from the modified A1aB1b proteins using a protease thermolysin.
The regions in the nucleotide sequence shown in SEQ ID NO:1, into which the DNA encoding (Aβ4-10)×3 was inserted using the respective primer sets are hereinafter referred to as the PS-1 region, PS-2 region, PS-3 region, PS-4 region and PS-5 region, respectively.
PCR was performed using 10 ng of pBSK-A1aB1b as a template and 50 μL/reaction of a reaction solution, by carrying out 1 cycle of 2 minutes of denaturation at 94° C. and then 25 cycles of 30 seconds of denaturation at 94° C., 30 seconds of annealing at 57° C. and 5 minutes of extension at 68° C. The reaction solution contained 200 μM dNTP mixture, 1.5 mM MgSO4 solution, each of the above primers at a concentration of 1 μM, and KOD-Plus-Ver.2 buffer containing 1 unit of KOD-Plus-(manufactured by Toyobo Co. Ltd.). The hereinafter-mentioned PCRs were carried out using the same composition except for the primers, unless otherwise specified.
Using DNA Ligation Kit (manufactured by TAKARA BIO), 50 fmol of each of the thus obtained DNA fragments and 150 fmol of the double-stranded DNA fragment encoding the above-described (Aβ4-10)×3 were subjected to ligation reaction at 16° C. for 40 minutes. The reaction product was used for transformation of E. coli DH5α competent cells (manufactured by TAKARA BIO) to obtain plural transformed E. coli cells. From the obtained E. coli cells, plasmid DNAs were extracted and purified, followed by analyzing their nucleotide sequences using the DNA sequencing service by FASMAC Co., Ltd. In the case where PS-1 was used, the result of the nucleotide sequence analysis of 12 clones of the transformed E. coli showed that one clone had one molecule of the double-stranded DNA fragment encoding (Aβ4-10)×3 in a state where the fragment was correctly inserted in the forward direction. Further, 24 clones, 54 clones, 30 clones and 12 clones were analyzed in the cases where PS-2, PS-3, PS-4 and PS-5 were used, respectively, and one each clone having one molecule of the double-stranded DNA fragment encoding (Aβ4-10)×3 in a state where the fragment was correctly inserted in the forward direction was obtained. The probability with which a modified A1aB1b gene wherein the fragment was correctly inserted can be obtained varied among the insertion sites, and insertion of the fragment was especially difficult in the case where PS-3 was used.
All of the thus prepared genes encoding modified A1aB1b were subjected to confirmation of their nucleotide sequences. Unless otherwise specified, the hereinafter-mentioned determination of nucleotide sequences was carried out using the DNA sequencing service by FASMAC Co., Ltd.
Subsequently, in order to prepare the modified A1aB1b genes wherein DNAs encoding (Aβ4-10)×3 are inserted in plural variable regions, PCR was carried out using the above-prepared genes encoding modified A1aB1b as templates and the primer sets that were the same as described above. Ligation reaction of the obtained DNA fragment and the double-stranded DNA fragment encoding the above-described (Aβ4-10)×3 peptide was repeated, to prepare the genes encoding modified A1aB1b. By this process, plasmids containing the genes encoding modified A1aB1b, in which DNAs encoding (Aβ4-10)×3 are inserted in plural variable regions of the A1aB1b gene, were prepared. The particular insertion regions, and the names of the genes encoding modified A1aB1b corresponding thereto are shown in Table 1.








TABLE 1






Region of insertion of DNA encoding (Aβ4-10) × 3,


Name
and number of inserted DNA







A1aB1bM1
one each in PS-1 region, PS-2 region and PS-4 region


A1aB1bM2
one in PS-1 region


A1aB1bM3
one in PS-2 region


A1aB1bM4-1
one in PS-3 region


A1aB1bM4-2
one in PS-4 region


A1aB1bM5
one each in PS-1 region, PS-2 region, PS-3 region,



PS-4 region and PS-5 region









To allow soybean seed-specific expression of the genes encoding modified A1aB1b prepared as described above, the promoter region and the terminator region of the wild-type A1aB1b gene were isolated.
Using, as a probe, the promoter region of the known partial genome sequence of the A1aB1b gene (GenBank accession No. X15121) containing a partial promoter sequence of the A1aB1b gene of 639 bp, a Misuzudaizu TAC library (www.kazusa.or.jp/ja/plant/PG2HP Transformation competent bacterial artificial chromosome) kept in National Agricultural Research Center for Hokkaido Region, National Agriculture and Food Research Organization was screened. As a result of analysis of the nucleotide sequence of the obtained clone, it was revealed that the promoter region located 2202 bp upstream of the translation initiation site of the A1aB1b gene was contained in the clone. Based on the obtained nucleotide sequence, a primer set composed of the oligonucleotide pair of SEQ ID NOs:16 and 17 was prepared, which primer set was then used for carrying out PCR in order to isolate the promoter region.
The above PCR was performed using the genomic DNA of Misuzudaizu as a template and 50 μL/reaction of a reaction solution, by carrying out 1 cycle of 2 minutes of denaturation at 94° C. and then 25 cycles of 30 seconds of denaturation at 94° C., 30 seconds of annealing at 57° C. and 2 minutes 30 seconds of extension at 68° C. By this process, a promoter fragment of the A1aB1b gene having a length of 2202 bp (Gy1P) (SEQ ID NO:18) was obtained.
Subsequently, in order to isolate the terminator region of the A1aB1b gene, a primer set composed of SEQ ID NOs:19 and 20 was prepared based on the known partial genomic sequence of the wild-type A1aB1b gene (GenBank accession No.X53404), which primer set was then used for carrying out PCR.
The above PCR was performed using the genomic DNA of Misuzudaizu as a template and 50 μL/reaction of a reaction solution, by carrying out 1 cycle of 2 minutes of denaturation at 94° C. and then 25 cycles of 30 seconds of denaturation at 94° C., 30 seconds of annealing at 57° C. and 1 minute of extension at 68° C. By this process, a terminator fragment of the wild-type A1aB1b gene having a length of 1052 bp (Gy1T) (SEQ ID NO:21) was obtained.
To allow seed-specific expression of the genes encoding modified A1aB1b, each of the genes encoding modified A1aB1b, and Gy1P and Gy1T, which were obtained as described above, were ligated with the known pUHG vector (Y. Kita, K. Nishizawa, M Takahashi, M. Kitayama, M. Ishimoto. (2007) Genetic improvement of somatic embryogenesis and regeneration in soybean and transformation of the improved breeding lines. Plant Cell Reports 26:439-447) (FIG. 3) to construct an expression plasmid.
In order to obtain DNA fragments encoding 5 types of modified A1aB1b among those described above, PCR was carried out using the above-described A1aB1bM2 (SEQ ID NO:22), A1aB1bM3 (SEQ ID NO:24), A1aB1bM4-1 (SEQ ID NO:26), A1aB1bM1 (SEQ ID NO:28) and A1aB1bM5 (SEQ ID NO:30) as templates, and the primer set composed of the oligonucleotide pair of SEQ ID NOs:32 and 33.
The above PCR was performed using 50 μL/reaction of a reaction solution, by carrying out 1 cycle of 2 minutes of denaturation at 94° C. and then 25 cycles of 30 seconds of denaturation at 94° C., 30 seconds of annealing at 57° C. and 2 minutes of extension at 68° C. By this process, a DNA fragment of each modified A1aB1b gene was obtained.
The DNA fragment of the modified A1aB1b gene, the promoter DNA fragment and the terminator DNA fragment were subjected to phosphorylation reaction, and then ligated into pUHG vector which had been preliminarily digested with SmaI and dephosphorylated with CIAP (manufactured by TAKARA BIO INC.). By analyzing the nucleotide sequences of the obtained clones, clones in which the Gy1P promoter, the gene encoding modified A1aB1b and the Gy1T terminator are correctly linked in this order were selected.
By this process, the following five types of plant transformation vectors (pUHG A1aB1bM1, pUHGA1aB1bM2, pUHGA1aB1bM3, pUHGA1aB1bM4-1 and pUHGA1aB1bM5) that express the genes encoding modified A1aB1b in a seed-specific manner were constructed.
Example 2
Construction of Expression Plasmid for Modified Common Bean Arcelin
Expression plasmids for expression, in soybean seeds, of genes encoding modified arcelin in which two copies of Aβ4-10 tandemly linked to each other (hereinafter abbreviated as (Aβ4-10)×2) are inserted were constructed.
Since the variable region(s) of the gene encoding the known common bean arcelin 5-1 (GenBank accession No. Z50202) (SEQ ID NO:36) has/have not been revealed, assumption of the variable region(s) was carried out. Based on assumption of the variable region(s) by comparison of the DNA sequence with that of A1aB1b, it was revealed that the disorder region is restricted to the C terminus. Therefore, it was thought that the peptide sequence may be inserted into the C terminus. In order to further specify the variable region, the DNA sequence of the gene was compared with that of phytohemagglutinin, which belongs to 2S albumin as arcelin does, and it was revealed that the loop structure of 8 to 10 residues found in phytohemagglutinin is absent in the downstream of the lysine (amino acid position 149 in SEQ ID NO:37), which is the corresponding portion in Arc5-1. Therefore, the nucleotide sequence region in SEQ ID NO:36 that encodes this portion (amino acid positions 149-150) was assumed to be the variable region A. Subsequently, arcelin 1 was compared with one of the storage proteins of common bean, phaseolin. As a result, a gap of 7 residues was found in the downstream of asparagine corresponding to amino acid position 250 of SEQ ID NO:37. Therefore, the nucleotide sequence region encoding this portion (amino acid positions 250-251) was assumed to be the variable region B.
In order to incorporate the DNA encoding (Aβ4-10)×2 into the assumed variable regions of the gene encoding Arc5-1, the oligonucleotide encoding (Aβ4-10)×2 (420F, SEQ ID NO:34) and the oligonucleotide complementary thereto (420R, SEQ ID NO:35) were synthesized.
In the presence of ATP at a final concentration of 1 mM, 100 pmol each of 420F and 420R was subjected to phosphorylation reaction with T4 Polynucleotide Kinase (manufactured by TAKARA BIO INC.), and the reaction solutions after the reaction were mixed together, followed by heating the resulting mixture at 94° C. for 10 minutes and then allowing the mixture to cool gradually to 37° C. for 1 hour, thereby carrying out annealing. By this process, a double-stranded DNA fragment encoding (Aβ4-10)×2 was obtained.
Using, as a template, the plasmid pBSK-Arc5-1 (kept in National Agricultural Research Center for Hokkaido Region, National Agriculture and Food Research Organization) obtained by inserting cDNA encoding Arc5-1 into the SmaI site of pBluescript II SK(−) (manufactured by Stratagene), PCR was carried out to obtain a DNA fragment containing the vector portion, such that the amino acid portion of a particular variable region of the gene encoding Arc5-1 is positioned at the ends. This DNA fragment was ligated with the double-stranded DNA fragment encoding (Aβ4-10)×2 synthesized as described above, to prepare a plasmid containing the gene encoding modified Arc5-1.
The method is more concretely described below.
A total of two primer sets, that is, the primer set (PS-A) composed of the primer pair of SEQ ID NOs:38 and 39 for insertion into the variable region A, and the primer set (PS-B) composed of the primer pair of SEQ ID NOs:40 and 41 for insertion into the variable region B, in the gene encoding Arc5-1 were prepared. The primers were synthesized such that nucleotide substitutions for introducing amino acid substitutions in the immediate upstream and downstream of the insertion regions were introduced in order to allow cleaving out of Aβ4-10 from the modified Arc5-1 proteins using a protease thermolysin.
The regions in the nucleotide sequence of SEQ ID NO:36, into which the DNA encoding (Aβ4-10)×2 was inserted using the respective primer sets are hereinafter referred to as the PS-A region and PS-B region, respectively.
PCR was carried out using 10 ng of pBSK-Arc5-1 as a template. This PCR was performed using 50 μL/reaction of a reaction solution, by carrying out 1 cycle of 2 minutes of denaturation at 94° C. and then 25 cycles of 30 seconds of denaturation at 94° C., 30 seconds of annealing at 57° C. and 4 minutes of extension at 68° C. The thus obtained DNA fragment and the double-stranded DNA fragment encoding the above-described (Aβ4-10)×2 were subjected to ligation reaction.
By this process, 2 types of plasmids containing a gene encoding modified Arc5-1, wherein the DNA encoding (Aβ4-10)×2 is inserted in a variable region of the gene encoding Arc5-1, were prepared. The particular insertion regions of the DNAs encoding (Aβ4-10)×2, and the names of the genes encoding modified Arc5-1 corresponding thereto are shown in Table 2.










TABLE 2








Region of insertion of DNA encoding (Aβ4-10) × 2,



Name
and number of inserted DNA









Arc5M1
one in PS-A region



Arc5M2
one in PS-B region










In order to allow soybean seed-specific expression of modified Arc5-1, each of the above obtained Arc5M1 and Arc5M2, and Gy1P and Gy1T derived from the A1aB1b gene in the above Example 1, were ligated with the pUHG vector to construct an expression plasmid. In order to obtain DNA fragments encoding modified Arc5-1, PCR was carried out using the above-described Arc5M1 and Arc5M2 as templates, and the primer set composed of the oligonucleotide pair of SEQ ID NOs:42 and 43.
The above PCR was performed using 50 μL/reaction of a reaction solution, by carrying out 1 cycle of 2 minutes of denaturation at 94° C. and then 25 cycles of 30 seconds of denaturation at 94° C., 30 seconds of annealing at 57° C. and 1 minute of extension at 68° C. By this process, a DNA fragment of each modified Arc5-1 gene was obtained.
The DNA fragment of the modified Arc5-1 gene, Gy1P and Gy1T were subjected to phosphorylation reaction, and then ligated into the pUHG vector which had been preliminarily digested with SmaI and dephosphorylated.
By this process, plant transformation vectors pUHG Arc5M1 and pUHG Arc5M2 that express the modified Arc5-1 genes in a seed-specific manner were constructed.
Example 3
Construction of Expression Plasmid for Modified Rice Prolamin
An expression plasmid for expression, in soybean seeds, of a gene encoding modified prolamin in which DNA encoding (Aβ4-10)×2 is inserted was constructed.
Since the variable region(s) of the gene encoding the known rice prolamin 10K, RP10 (GenBank accession No. E09782) (SEQ ID NO:44), has/have not been revealed, assumption of the variable region(s) was carried out. The amino acid sequence of RP10 was compared with that of zein delta, which is one of the major storage proteins in maize. As a result, a gap of 11 residues was found in the downstream of lysine corresponding to amino acid position 110 of SEQ ID NO:45. Therefore, the nucleotide sequence region encoding this portion (amino acid positions 110-111) was assumed to be the variable region a.
Subsequently, using, as a template, the plasmid pBSK-RP10 (kept in National Agricultural Research Center for Hokkaido Region, National Agriculture and Food Research Organization) obtained by cloning the cDNA encoding the rice prolamin 10K, RP10, into the SmaI site of pBluescript II SK(−) (manufactured by Stratagene), PCR was carried out to obtain a DNA fragment containing the vector portion, such that the amino acid portion of the particular variable region a of the gene encoding RP10 is positioned at the ends. This DNA fragment was ligated with the double-stranded DNA fragment encoding (Aβ4-10)×2 synthesized in Example 2, to prepare a plasmid containing a gene encoding modified RP10.
The method is more concretely described below.
A primer set composed of the primer pair of SEQ ID NOs:46 and 47 for insertion into the variable region a in the gene encoding RP10 was prepared. The primers were synthesized such that nucleotide substitutions for introducing amino acid substitutions in the immediate upstream and downstream of the insertion region were introduced in order to allow cleaving out of the Aβ4-10 peptide from the modified RP10 protein using a protease thermolysin.
PCR was carried out using 10 ng of pBSK-RP10 as a template. This PCR was performed using 50 μL/reaction of a reaction solution, by carrying out 1 cycle of 2 minutes of denaturation at 94° C. and then 25 cycles of 30 seconds of denaturation at 94° C., 30 seconds of annealing at 57° C. and 4 minutes of extension at 68° C. Each of the obtained DNA fragments and the double-stranded DNA fragment encoding the above-described (Aβ4-10)×2 were subjected to ligation reaction.
By this process, a plasmid (RP10M1) containing a gene encoding modified RP10, wherein the DNA encoding (Aβ4-10)×2 is inserted in the variable region of the gene encoding RP10, was prepared.
In order to allow seed-specific expression of the gene encoding modified RP10, the gene encoding modified RP10, and Gy1P and Gy1T obtained in the above Example 1 were ligated with the pUHG vector to construct an expression plasmid. In order to obtain a DNA fragment encoding modified RP10, PCR was carried out using the above-described RP10M1 as a template, and the primer set composed of SEQ ID NOs:48 and 49.
The above PCR was performed using 50 μL/reaction of a reaction solution, by carrying out 1 cycle of 2 minutes of denaturation at 94° C. and then 25 cycles of 30 seconds of denaturation at 94° C., 30 seconds of annealing at 57° C. and 1 minute of extension at 68° C. By this process, a DNA fragment encoding modified RP10 was obtained.
The DNA fragment encoding modified RP10, and the promoter DNA fragment and the terminator DNA fragment were subjected to phosphorylation reaction, and then ligated into the pUHG vector which had been preliminarily digested with SmaI and dephosphorylated.
By this process, a plant transformation vector pUHG RP10M1 that expresses the gene encoding modified RP10 in a seed-specific manner was constructed.
Example 4
Construction of Expression Plasmids for Respective Modified Types Using Arcelin 2 Promoter
Expression plasmids for expressing, in soybean seeds, the genes encoding modified A1aB1b prepared in Example 1 with a common bean-derived arcelin 2 promoter were constructed.
(1) Isolation of Common Bean-Derived Arcelin 2 Promoter
From 1 g of fresh leaves of the wild species of common bean (line number: G12866), 50 μg of genomic DNA was extracted using DNeasy Plant Maxi kit (manufactured by QIAGEN).
After digesting 280 ng of the genomic DNA with the restriction enzyme SauIIIAI, dGTP was added to the resulting digestion product, followed by carrying out single-nucleotide extension reaction (the first extension reaction) using klenow enzyme (manufactured by Promega KK). Thereafter, the reaction product was ligated with the RWA-1 adapter included in RightWalk KitTM using Ligation high (manufactured by Toyobo Co., Ltd.), and the resulting ligation product was used as a template for PCR to isolate the DNA in the upstream region of the arcelin 2 gene.
Subsequently, based on the nucleotide sequence of cDNA of the known common bean arcelin 2 gene (GenBank accession No. M28470), oligonucleotides having the nucleotide sequences shown in SEQ ID NOs: 50 and 51 (which were designated the primer SP1 and the primer SP2, respectively) were prepared using the custom synthesis service by FASMAC Co., Ltd.












(primer SP1)
SEQ ID NO: 50











TTGGTTTTGT TGAACGTCTC GAC



 












(primer SP2)
SEQ ID NO: 51











GGTGAGAAGC ACAAGGAAGA GG






Thereafter, PCR was carried out using, as a template, 2.8 ng of the above-constructed genomic DNA to which the adapter was ligated, the primer WP-1 included in RightWalk KitTM and the primer SP1. The above PCR was performed using 50 μL/reaction of a reaction solution, by carrying out 1 cycle of 2 minutes of denaturation at 94° C. and then 35 cycles of 30 seconds of denaturation at 94° C., 30 seconds of annealing at 65° C. and 5 minutes of extension at 68° C. The reaction solution contained 200 μM dNTP mixture, 1.5 mM MgSO4 solution, each of the above primers at a concentration of 1 μM, and KOD-Plus-Ver.2 buffer containing 1 unit of KOD-Plus-(manufactured by Toyobo Co. Ltd.).
Thereafter, the reaction solution was 100-fold diluted, and the second PCR was carried out using 1 μL of the resulting dilution as a template, the primer WP-2 included in RightWalk KitTM and the primer SP2. The composition of the solution and the temperature conditions in the second PCR were the same as those in the first PCR except for the template and the primers.
The amplified DNA fragment was subjected to phosphorylation reaction with T4 Polynucleotide Kinase (manufactured by TAKARA BIO INC.) in the presence of ATP at a final concentration of 1 mM, and then ligated with pBluescriptII SK(−) (manufactured by Stratagene) that had been preliminarily treated with SmaI.
This reaction product was designated Arc2P(i), and its nucleotide sequence was determined using the DNA sequencing service by FASMAC Co., Ltd. As a result, it was confirmed that the product contains a novel region having a length of 844 bp in the upstream of the initiation codon of the arcelin 2 gene.
Thereafter, in order to isolate the region located further upstream, new primers were prepared to carry out the second elongation reaction.
After digesting 280 ng of the genomic DNA with the restriction enzyme BglII, dGTP was added to the resulting digestion product, followed by carrying out single-nucleotide extension reaction using klenow enzyme (manufactured by Promega KK). Thereafter, the reaction product was ligated with the RWA-1 adapter included in RightWalk KitTM, and the resulting ligation product was used as a template for PCR to isolate the promoter.
Subsequently, based on the nucleotide sequence of cDNA of the known common bean arcelin 2 gene (GenBank accession No. M28470), an oligonucleotide having the nucleotide sequence shown in SEQ ID NO:52 (which was designated the primer secondSP1) was prepared, and, based on the nucleotide sequence located in a region of 844 bp upstream of the initiation codon, which was obtained in the first extension reaction, an oligonucleotide having the nucleotide sequence shown in SEQ ID NO:53 (which was designated the primer secondSP2) was prepared.












(primer secondSP1)
SEQ ID NO: 52











CAGATTTTTT GCCCTCAAAA TTGATG



 












(primer secondSP2)
SEQ ID NO: 53











CGGATGTGCG TGGACTACAA GG






Thereafter, PCR was carried out using, as a template, 2.8 ng of the above-constructed genomic DNA to which the adapter was ligated, the primer WP-1 included in RightWalk KitTM and the primer secondSP1. The composition of the solution and the temperature conditions in the PCR were the same as those in the above-described first extension reaction except for the template and the primers.
Thereafter, the above PCR solution was 100-fold diluted, and the second PCR was carried out using 1 μL of the resulting dilution as a template, the primer WP-2 included in RightWalk KitTM and the primer secondSP2. The composition of the solution and the temperature conditions in the second PCR were the same as those in the first PCR except for the template and the primers.
The amplified DNA fragment was subjected to phosphorylation reaction with T4 Polynucleotide Kinase (manufactured by TAKARA BIO INC.) in the presence of ATP at a final concentration of 1 mM, and then ligated with pBluescriptII SK(−) (manufactured by Stratagene) that had been preliminarily treated with SmaI.
This reaction product was designated Arc2P(ii), and its nucleotide sequence was determined. Thereafter, in order to isolate the region located further upstream, new primers were prepared to carry out the third elongation reaction.
After digesting 280 ng of the genomic DNA with the restriction enzyme XbaI, dCTP was added to the resulting digestion product, followed by carrying out single-nucleotide extension reaction using klenow enzyme (manufactured by Promega KK). Thereafter, the reaction product was ligated with the RWA-2 adapter included in RightWalk KitTM, and the resulting ligation product was used as a template for PCR to isolate the promoter.
Subsequently, based on the nucleotide sequence of 197 bp obtained in the second extension reaction, oligonucleotides having the nucleotide sequences shown in SEQ ID NOs: 54 and 55 (which were designated the primer thirdSP1 and the primer thirdSP2, respectively) were prepared.












(primer thirdSP1)
SEQ ID NO: 54











CGACCTGAAG AACGCAGCGG CGACC



 












(primer thirdSP2)
SEQ ID NO: 55











TACCAGCAGT TGATGGACAA GATC






Thereafter, PCR was carried out using, as a template, 2.8 ng of the above-constructed genomic DNA to which the adapter was ligated, the primer WP-1 included in RightWalk KitTM and the primer thirdSP1. The composition of the solution and the temperature conditions in the PCR were the same as those in the above-described first extension reaction except for the template and the primers.
Thereafter, the above PCR solution was 100-fold diluted, and the second PCR was carried out using 1 μl, of the resulting dilution as a template, the primer WP-2 included in RightWalk KitTM and the primer thirdSP2. The composition of the solution and the temperature conditions in the second PCR were the same as those in the first PCR except for the template and the primers.
The amplified DNA fragment was subjected to phosphorylation reaction with T4 Polynucleotide Kinase (manufactured by TAKARA BIO INC.) in the presence of ATP at a final concentration of 1 mM, and then ligated with pBluescriptII SK(−) (manufactured by Stratagene) that had been preliminarily treated with SmaI.
This reaction product was designated Arc2P(iii), and its nucleotide sequence was determined. As a result it was confirmed that the product contains a novel region having a length of 2819 bp in the upstream of Arc2P(ii) (3860 bp in total). Thus, by the three times of extension reaction, DNA(Arc2P) having a length of 3860 bp which contains the 5′-untranslated region in the upstream of the initiation codon of the arcelin 2 gene, wherein the novel promoter sequence is included, was obtained (SEQ ID NO:56, in which the promoter region corresponds to nucleotide positions 1399-3860).
(2) Isolation of Common Bean-Derived Arcelin 2 Terminator
After digesting 280 ng of the genomic DNA extracted in the above (1) with the restriction enzyme NheI, dCTP was added to the resulting digestion product, followed by carrying out single-nucleotide extension reaction using klenow enzyme (manufactured by Promega KK). Thereafter, the reaction product was ligated with the RWA-2 adapter included in RightWalk KitTM using Ligation high (manufactured by Toyobo Co., Ltd.), and the resulting ligation product was used as a template for PCR to isolate the terminator gene.
Subsequently, based on the nucleotide sequence of cDNA of the known common bean arcelin 2 gene (GenBank accession No. M28470), oligonucleotides having the nucleotide sequences shown in SEQ ID NOs:57 and 58 (which were designated the primer SP3 and the primer SP4, respectively) were prepared.












(primer SP3)
SEQ ID NO: 57











CATCAATTTT GAGGGCAAAA AATCTG



 












(primer SP4)
SEQ ID NO: 58











CGTTCCAACA TCCTCCTCAA CAAGATC






Thereafter, PCR was carried out using, as a template, 2.8 ng of the above-constructed genomic DNA to which the adapter was ligated, the primer WP-1 included in RightWalk KitTM and the primer SP3. The above PCR was performed using 50 μL/reaction of a reaction solution, by carrying out 1 cycle of 2 minutes of denaturation at 94° C. and then 35 cycles of 30 seconds of denaturation at 94° C., 30 seconds of annealing at 65° C. and 5 minutes of extension at 68° C. The reaction solution contained 200 μM dNTP mixture, 1.5 mM MgSO4 solution, each of the above primers at a concentration of 1 μM, and KOD-Plus-Ver.2 buffer containing 1 unit of KOD-Plus-(manufactured by Toyobo Co. Ltd.).
Thereafter, the reaction solution was 100-fold diluted, and the second PCR was carried out using 1 μL of the resulting dilution as a template, the primer WP-2 included in RightWalk KitTM and the primer SP4. The composition of the solution and the temperature conditions in the second PCR were the same as those in the first PCR except for the template and the primers.
The amplified DNA fragment was subjected to phosphorylation reaction with T4 Polynucleotide Kinase (manufactured by TAKARA BIO INC.) in the presence of ATP at a final concentration of 1 mM, and then ligated with pBluescriptII SK(−) (manufactured by Stratagene) that had been preliminarily treated with SmaI.
This reaction product was designated Arc2T, and its nucleotide sequence was determined. As a result, it was confirmed that the product contains a novel region having a length of 795 bp in the downstream of the stop codon of the arcelin 2 gene wherein the 3′-untranslated region is included (SEQ ID NO:59).
(3) Construction of Various Modified Expression Plasmids
In order to express the genes encoding modified A1aB1b in seeds, the genes encoding various modified A1aB1b obtained in Example 1, and Arc2P and Arc2T were ligated with the known pUHG vector (mentioned above, FIG. 3), to construct expression plasmids.
The DNA fragment of each modified A1aB1b gene, the promoter DNA fragment and the terminator DNA fragment were subjected to phosphorylation reaction, and then ligated with the pUHG vector that had been preliminarily digested with SmaI and dephosphorylated with CIAP (manufactured by TAKARA BIO INC.). By analyzing the nucleotide sequences of the obtained clones, clones in which the Arc2P promoter, the gene encoding modified A1aB1b and the Arc2T promoter are correctly linked in this order were selected.
By this process, the following five types of plant transformation vectors (pUHGA2PA1aB1bM1, pUHGA2PA1aB1bM3 and pUHGA2PA1aB1bM5) that express the genes encoding modified A1aB1b under the control of the arcelin 2 promoter in a seed-specific manner were constructed.
In the same manner, a plant transformation vector pUHGA2PRP10M1 that expresses the gene encoding the above-mentioned RP10M1 in a seed-specific manner was constructed.
Example 5
Introduction of Gene Encoding Modified Seed Storage Protein to Soybean
By the known method (K. Nishizawa, Y. Kita, M. Kitayama, M. Ishimoto. (2006) A red fluorescent protein, DsRed2, as a visual reporter for transient expression and stable transformation in soybean. Plant Cell Reports 25:1355-1361), 30 adventitious embryonic masses (with diameters of not more than 3 mm) were induced from immature seeds of the soybean variety Jack and a mutant line deficient for 11S globulin and 7S globulin that are major seed storage proteins (kept in National Agricultural Research Center for Hokkaido Region, National Agriculture and Food Research Organization) (Y. Kita, K. Nishizawa, M Takahashi, M. Kitayama, M. Ishimoto. (2007) Genetic improvement of somatic embryogenesis and regeneration in soybean and transformation of the improved breeding lines. Plant Cell Reports 26:439-447), and these adventitious embryonic masses were placed in 1.5 ml tubes, followed by carrying out the gene transfer operation by the whisker ultrasonic method (JP 3312867 B).
In a 1.5 ml tube, 5 mg of whiskers made of potassium titanate LS20 (manufactured by Titan Kogyo, Ltd.) were placed, and the tube was left to stand for 1 hour, followed by removing and completely distilling ethanol to obtain sterile whiskers. Into the tube containing the whiskers, 1 ml of sterile water was added, and the resulting mixture was stirred well. The mixture of whiskers and sterile water was subjected to centrifugation, and water as the supernatant was discarded. In such a manner, the whiskers were washed. This washing operation for the whiskers was repeated 3 times. Thereafter, 0.5 ml of the known MS liquid medium was added to the tube to obtain a whisker suspension.
To the tube containing the whisker suspension obtained as described above, the above-described 30 adventitious embryonic masses (with diameters of not more than 3 mm) were added, and the resulting mixture was stirred, followed by centrifuging the mixture at 1000 rpm for 10 seconds to precipitate the adventitious embryonic masses and the whiskers. The supernatant was discarded to obtain a mixture of the adventitious embryonic masses and the whiskers.
Into the tube containing the above mixture, 20 μl (20 μg) each of the expression vectors for the modified seed storage proteins prepared in Examples 1 to 4 was added, and the resulting mixture was sufficiently mixed by shaking to obtain a uniform mixture.
Subsequently, this tube containing the uniform mixture was subjected to centrifugation at 18000×g for 5 minutes. The mixture after the centrifugation was mixed by shaking again. This operation was repeated 3 times.
The thus obtained tube containing the adventitious embryonic masses, the whiskers and the vector was placed in the bath of an ultrasonic generator such that the tube was sufficiently soaked therein. An ultrasonic wave with a frequency of 40 kHz was radiated to the tube at an intensity of 0.25 W/cm2 for 1 minute. Thereafter, this mixture was left to stand for 10 minutes at 4° C. The mixture processed with ultrasonication in such a manner was washed with the above-described MS liquid medium.
The processed adventitious embryonic masses were cultured in the known liquid medium for growing adventitious embryos for 1 week by rotary shaking culture (100 rpm), and then cultured in a fresh liquid medium for growing adventitious embryos containing hygromycin B (15 mg/l) (Roche Diagnostics, Mannheim, Germany) for 1 week. Further, the adventitious embryonic masses were cultured in a liquid medium for growing adventitious embryos containing 30 mg/l hygromycin B for 4 weeks (while exchanging the medium every week), and then subjected to selection culture in a liquid medium for growing adventitious embryos containing 45 mg/l hygromycin B for 1 week. The gene transfer was carried out for 12 microtubes per vector.
Hygromycin-resistant adventitious embryonic masses were transferred to a liquid medium for maturation of adventitious embryos, and the culture was continued with shaking (100 rpm) for 4 weeks to allow maturation of the adventitious embryos. The mature adventitious embryos were dried by being left to stand in a sterile Petri dish for 3 to 5 days, and then transferred to the known solid medium for germination. After carrying out germination culture for 7 to 10 days, the embryos were transferred to the known rooting medium, thereby allowing the germinated seedlings to grow. After the growth of roots and buds, the plants were transferred to a pot containing soil, and high humidity was maintained until acclimation.
Example 6
Preparation of Transformed Soybean Plant to which Modified Seed Storage Protein Gene was Introduced
By such a process, 6 individuals of transformed soybean plants produced by introducing A1aB1BM1, 6 individuals of transformants produced by introducing A1aB1bM2, 5 individuals of transformants produced by introducing A1aB1bM3, 5 individuals of transformants produced by introducing A1aB1bM4-1, and 9 individuals of transformants produced by introducing A1aB1bM5, to the Jack variety were prepared. Further, 3 individuals of transformed soybean plants to which Arc5M1 was introduced, 3 individuals of transformants to which Arc5M2 was introduced, and 2 individuals of transformed soybean plants to which RP10M1 was introduced were prepared.
Further, 12 individuals of transformed soybean plants produced by introducing A1aB1bM1, and 6 individuals of transformed soybean plants produced by introducing RP10M1, to the above-described mutant line deficient for 11S globulin and 7S globulin (hereinafter referred to as the seed storage protein-deficient variety) were prepared.
Further, 5 individuals of transformed soybean plants produced by introducing A1aB1bM3 to the seed storage protein-deficient variety were prepared.
Further, 8 individuals of transformants produced by introducing A2PA1aB1bM1, 33 individuals of transformants produced by introducing A2PA1aB1bM3, 32 individuals of transformants produced by introducing A2PA1aB1bM5, and 9 individuals of transformants produced by introducing A2PRP10M1, to the seed storage protein-deficient variety were prepared.
These plant bodies of transformed soybean were acclimatized to ambient humidity, and the cultivation was continued under the conditions of 10000 1× and illumination for 16 hours per day, after which seeds were harvested from all the individuals. By such a process, seeds of the transformed soybean plants of the T1 generation were obtained.
Example 7
Evaluation of Amount of Aβ4-10 Accumulated in Seeds of Transformed Soybean
Total protein was extracted from the seeds of the transformed soybeans obtained in the above Example 6, and the accumulated amount of Aβ4-10 was evaluated by Western blotting using an antibody specific to Aβ4-10. For lines having large accumulated amounts, quantitative analysis was carried out.
1) Amount of Accumulation of Aβ4-10 Expressed as Modified A1aB1b
20 μg of total protein extracted from seeds of each transformed soybean was separated by SDS-PAGE, and allowed to react with an antibody specific to Aβ4-10, followed by detection using ECL Advance Western Blotting Detection Kit (manufactured by GE Healthcare Bio-Science KK). A chemiluminescence image was captured by LAS4000miniPR (manufactured by FUJIFILM Corporation), and quantitative analysis was carried out using MultiGage, which is an analysis software included in the apparatus. As a standard sample for quantification, a His-Tag-linked recombinant protein A1aB1bM1 prepared by the E. coli expression system was used.
As a result, the signal band corresponding to Aβ4-10 was confirmed for each line of the transformed soybean seeds obtained in the above Example 6, so that accumulation of Aβ4-10 was confirmed. Among the lines, the transformed soybean seeds prepared by introducing A1aB1bM1, A1aB1bM3 and A1aB1bM5 to the Jack variety (lines No. 10-2, No. a-2 and No. 6-6) and the transformed soybean seeds prepared by introducing A1aB1bM1 to the seed storage protein-deficient variety (line No. 16-2), in which Aβ4-10 was highly accumulated, were subjected to measurement of the amounts of accumulation of Aβ4-10. The results are shown in Table 3.










TABLE 3








Amount of accumulated





Aβ4-10 (μg/1 g


Modified gene
Variety
Line No.
seed weight)


















A1aB1bM1
Jack
10-2
35


A1aB1bM1
Deficient variety
16-2
870


A1aB1bM3
Jack
 a-2
42


A1aB1bM5
Jack
 6-6
108









Further, comparison of the accumulated amounts of the modified seed storage protein in the transformed soybeans prepared by introducing A1aB1BM1 (the gene in which three copies of Aβ4-10 are inserted) to the Jack variety and to the seed storage protein-deficient variety was carried out by Western blot analysis. The results are shown in FIG. 4 (wherein the arrowheads indicate the bands corresponding to the modified seed storage proteins). As a result, it was confirmed that the amounts of accumulation of the modified seed storage protein in the transformant line 10-2 prepared by introducing A1aB1M1 to the Jack variety (seed Nos. 1 to 3) were about 0.1 to 0.2% with respect to the total protein in the seeds, while the amounts of accumulation of the modified seed storage protein in the transformant line 16-2 prepared by introducing A1aB1M1 to the seed storage protein-deficient line (seed Nos. 1 to 3) were about 1 to 2% with respect to the total protein in the seeds, which values were about 10 times higher than those in the above case.
Further, the accumulated amount of the modified seed storage protein in the transformed soybeans prepared by introducing A1aB1BM3 (the gene in which a single copy of Aβ4-10 is inserted) to the seed storage protein-deficient variety was measured by Western blot analysis. The results are shown in Table 4.










TABLE 4








Amount of accumulated





Aβ4-10 (μg/1 g


Modified gene
Variety
Line No.
seed weight)







A1aB1bM3
Deficient variety
5-2
1568




5-6
2504




7-3
2348









2) Amount of Accumulation of Aβ4-10 Expressed as Modified Arcelin

20 μg of total protein extracted from seeds of each transformed soybean was separated by SDS-PAGE, and allowed to react with an antibody specific to Aβ4-10, followed by Western blot detection of Aβ4-10 using ECL Advance Western Blotting Detection Kit (manufactured by GE Healthcare Bio-Science KK). As a result, the signal bands corresponding to the Aβ4-10 peptide was confirmed for the transformed soybean seeds to which Arc5M1 was introduced (line 2-1) and the transformed soybean seeds to which Arc5M2 was introduced (line 2-2), so that accumulation of Aβ4-10 was confirmed (FIG. 5).
3) Amount of Accumulation of Aβ4-10 Expressed as Modified Prolamin
20 μg of total protein extracted from seeds of the RP10M1-transformed soybean (lines 1-1 and 4-2) was separated by SDS-PAGE, and allowed to react with an antibody against Aβ4-10, followed by Western blot detection using ECL Advance Western Blotting Detection Kit (manufactured by GE Healthcare Bio-Science KK). As a result, the signal bands corresponding to the Aβ4-10 peptide was confirmed for the transformed soybean seeds of the respective lines to which PR10M1 was introduced, so that accumulation of the Aβ4-10 peptide was confirmed (FIG. 6).
Similarly, the signal bands corresponding to the Aβ4-10 peptide was confirmed for the seeds of the RP10M1-transformed soybean, so that accumulation of Aβ4-10 was confirmed. The accumulated amount in this case was about 380 μg/g seed for the No. 1-1 line.
4) Amount of Accumulation of Aβ4-10 Expressed as Modified A1aB1b by Arcelin 2 Promoter
20 μg of total protein extracted from seeds of each transformed soybean was separated by SDS-PAGE, and subjected to the detection in the same manner as in 1) in Example 7.
As a result, the signal bands corresponding to Aβ4-10 was confirmed for the respective lines of transformed soybean seeds obtained in the above Example 6, so that accumulation of Aβ4-10 was confirmed (FIG. 7).
Further, it was confirmed that the amount of accumulation of Aβ4-10 in the transformed soybean seeds prepared by introduction of the gene into the seed storage protein-deficient variety, which amount of accumulation was assumed based on the intensity of the signal band, for A2PA1aB1bM1 (line 4-6) was almost equivalent to that for A1aB1bM1 (line 7-1), and that these amounts of accumulation were clearly larger than those for A1aB1bM1 (line 8-1) prepared by introduction of the gene into the Jack variety (FIG. 7).
Example 8
Assay of Effect of Modified Seed Storage Protein
A1aB1bM1 prepared in the above Example 1 was expressed in E. coli by the known method, to produce the protein.
In order to obtain the recombinant protein encoded by A1aB1bM1, the E. coli expression plasmid pETA1aB1bM1 was prepared by ligating A1aB1bM1 with the pET21-d vector (manufactured by Novagen).
The above-described pETA1aB1bM1 was introduced to E. coli AD494 (manufactured by Novagen) by a conventional method, and the recombinant E. coli was cultured in 50 ml of the known TB medium (supplemented with kanamycin at a final concentration of 15 mg/l and carbenicillin at a final concentration of 50 mg/l) at 37° C. for 18 hours, followed by adding 10 ml of the culture to 1000 ml of the known LB medium (supplemented with kanamycin at a final concentration of 15 mg/l, carbenicillin at a final concentration of 50 mg/l and sodium chloride at a final concentration of 500 mM) as a production medium and carrying out culture at 37° C. for 2 hours. Thereafter, IPTG was added to a final concentration of 1 mM, and the recombinant E. coli was then cultured at 20° C. for 48 hours. The cells of E. coli after the culture were collected by centrifugation at 8000 rpm for 15 minutes. From the bacterial cells after the collection, the fraction of soluble protein was extracted using BugBuster Protein Extraction Reagent (manufactured by Novagen). From the obtained fraction of soluble protein, the recombinant protein encoded by A1aB1bM1 (A1aB1bM1 protein) was purified using Ni-NTA His-Bind Resins (manufactured by Novagen).
In physiological saline, 50 μg of A1aB1bM1 having the β-amyloid antigenic determinant (Aβ4-10) was dissolved, and the resulting solution was administered to Alzheimer's disease model mice (TgCRND8) of 4-weeks old five times at intervals of 1 week by subcutaneous injection (3 individuals/group). A control group was prepared by expressing the unmodified gene encoding the wild-type A1aB1b in E. coli in the same manner as described above, and administering the obtained wild-type A1aB1b to the mice. Nine weeks after the administration, blood was collected from the mice, and production of antibodies against Aβ4-10 was confirmed by the known sandwich method by ELISA. The antibody titer was evidently higher in the group to which the A1aB1bM1 protein was administered compared to the group to which the A1aB1b protein was administered, so that the vaccine effect of the recombinant protein encoded by A1aB1bM1 was confirmed.
Example 9
Thermal Stability of Modified Seed Storage Protein in Soybean Seeds
The transformed soybean seeds obtained in the above Example 6 were subjected to various heat treatments to test the thermal stability of the modified seed storage protein in the seeds.
1) Roasted Group of Transformed Soybean Seeds
The A1aB1bM3-transformed soybean seeds were pulverized, and 10 mg of the pulverized product was processed in an autoclave sterilization equipment at 100° C. for 10 minutes, followed by extracting total protein by the method described in the above Example 7 and evaluating the amount of accumulation of Aβ4-10 in the seeds by Western blotting using an antibody specific to Aβ4-10.
2) Water-Boiled Group of Transformed Soybean Seeds
The A1aB1bM3-transformed soybean seeds were pulverized, and 30 μl of distilled water was added to 10 mg of the pulverized product, and the resultant was processed in an autoclave sterilization equipment at 100° C. for 10 minutes, followed by extracting total protein by the method described in the above Example 7 and evaluating the amount of accumulation of Aβ4-10 in the seeds by Western blotting using an antibody specific to Aβ4-10.
3) Group in which Extract from Transformed Soybean Seeds was Heat-Treated
The A1aB1bM3-transformed soybean seeds were pulverized, and total protein was extracted by the method described in the above Example 7, followed by processing the total protein in an autoclave sterilization equipment at 100° C. for 10 minutes. Thereafter, the amount of accumulation of Aβ4-10 in the seeds was evaluated by Western blotting using an antibody specific to Aβ4-10.
As a result, the signal bands corresponding to Aβ4-10 was confirmed in the roasted group and the water-boiled group. It was confirmed that the amounts were equivalent to that in the heat-untreated group, and hence that the modified seed storage protein in the seeds is heat-stable (FIG. 8).
Example 10
Form of β-Amyloid Antigenic Determinant
The peptide having the amino acid sequence encoding Aβ4-10 (P1), the peptide having the amino acid sequence wherein two copies of P1 are tandemly linked (P2), and the peptide having the amino acid sequence wherein three copies of P1 are tandemly linked (P3) were synthesized using a custom peptide synthesis service.











(SEQ ID NO: 3)




P1: FRHDSGY



 




(SEQ ID NO: 60)




P2: FRHDSGY FRHDSGY



 




(SEQ ID NO: 61)




P3: FRHDSGY FRHDSGY FRHDSGY






Subsequently, KLH-P1, KLH-P2 and KLH-P3, wherein a carrier protein key-limpet-hemocyanin (KLH, Mw. 1000000) is linked to the N-termini of the peptides P1, P2 and P3, respectively, through cysteine (Cys) as a cross-linker, were prepared.
In physiological saline, 50 μg each of these KLH-P1, KLH-P2 and KLH-P3 was dissolved, and the resulting solution was administered to mice (BALBc) of 4-weeks old five times at intervals of 1 week by subcutaneous injection (3 individuals/group). Nine weeks after the administration, blood was collected from the mice to collect antiserum. The obtained antiserum was affinity-purified to prepare purified antibodies against KLH-P1, KLH-P2 and KLH-P3.
Commercially available synthetic Aβ42 in amounts of 400 and 1000 picomoles was subjected to electrophoresis by SDS-PAGE, and the above-described purified antibodies against KLH-P1, KLH-P2 and KLH-P3 were allowed to react with the Aβ42, followed by detection using ECL Advance Western Blotting Detection Kit (manufactured by GE Healthcare Bio-Science KK). The chemiluminescence image was captured by LAS4000miniPR (manufactured by FUJIFILM Corporation), and the signal intensities were compared to assume the binding capacities of the antibodies to Aβ42. As a result, it was shown that the signal intensity for KLH-P2 was evidently stronger than the signal intensities for KLH-P1 and KLH-P3, and hence that a specific antibody having a high antibody titer against Aβ can be obtained by tandemly linking two copies of the peptide having the amino acid sequence encoding Aβ4-10 (FIG. 9).
Example 11
Construction of Expression Plasmid for Modified Soybean Protein in which Amyloid β Antigenic Peptide is Inserted
Aβ1-15 Antigenic Peptide
A plasmid for expression of a gene encoding a modified A1aB1b comprising the β-amyloid antigenic determinant peptide of SEQ ID NO:62 (hereinafter abbreviated as Aβ15) in soybean seeds was constructed.
An oligonucleotide having two copies of the nucleotide sequence encoding Aβ15 which are tandemly linked to each other via two lysine codons (the sense strand, SEQ ID NO:64) and the oligonucleotide having its complementary sequence (the antisense strand, SEQ ID NO:65) were synthesized using the custom DNA synthesis service by FASMAC Co., Ltd. (the sense strand and the antisense strand are hereinafter referred to as AB15F and AB15R, respectively). In the presence of ATP at a final concentration of 1 mM, 100 pmol each of AB15F and AB15R was subjected to phosphorylation reaction with T4 Polynucleotide Kinase (manufactured by TAKARA BIO INC.), and the reaction solutions after the reaction were mixed together, followed by heating the resulting mixture at 94° C. for 10 minutes and then allowing the mixture to cool gradually to 37° C. for 1 hour, thereby carrying out annealing. By this process, a double-stranded DNA fragment encoding a peptide wherein two copies of Aβ15 are tandemly linked to each other via two lysine residues (Aβ15×2) was obtained.
Using, as a template, the plasmid pBSK-A1aB1b, wherein cDNA of a known A1aB1b gene (GenBank accession No. AB 113349) is cloned at the SmaI site of pBluescript II SK(−) (manufactured by Stratagene), PCR was carried out to amplify a fragment containing the vector portion such that the 5′-end and the 3′-end of the fragment are positioned at a specific variable region of the gene encoding A1aB1b. The obtained DNA fragment was ligated with the above-obtained double-stranded DNA fragment encoding Aβ15×2, to prepare a plasmid containing the gene encoding a modified A1aB1b. The method is more concretely described below.
A primer set composed of the primer pairs of SEQ ID NOs:66 and 67 for insertion into the variable region III of the gene encoding A1aB1b of SEQ ID NO:2 was prepared (primer set for PS-2).
The region in the nucleotide sequence of SEQ ID NO:1, into which the DNA encoding (Aβ15×2) is inserted using the primer set is hereinafter referred to as the PS-2 region.
PCR was performed using 10 ng of pBSK-A1aB1b as a template. In the PCR, 50 μL/reaction of a reaction solution was used, and 2 minutes of denaturation at 94° C. and subsequent 25 cycles of 30 seconds of denaturation at 94° C., 30 seconds of annealing at 57° C. and 5 minutes of extension at 68° C. were performed. The reaction solution contained 200 μM dNTP mixture, 1.5 mM MgSO4 solution, each of the above primers at a concentration of 1 μM, and KOD-Plus-Ver.2 buffer containing 1 unit of KOD-Plus- (manufactured by Toyobo Co. Ltd.). The hereinafter-mentioned PCR was carried out using the same composition except for the primers, unless otherwise specified.
Using DNA Ligation Kit (manufactured by TAKARA BIO), 50 fmol of the amplified DNA fragment and 150 fmol of the double-stranded DNA fragment encoding the above-described Aβ15×2 were subjected to ligation reaction at 16° C. for 40 minutes. The ligation product was used for transformation of E. coli DH5α competent cells (manufactured by TAKARA BIO), to obtain plural transformed E. coli cells. From the obtained E. coli, plasmid DNA was extracted and purified, followed by confirming the nucleotide sequence of the gene encoding the modified A1aB1b (hereinafter referred to as A1aB1bMK1).
Example 12
Construction of Expression Plasmid for Modified Soybean Protein in which Amyloid β Antigenic Peptide is Inserted
Aβ4-10 Antigenic Peptide
A plasmid for expression of a gene encoding a modified A1aB1b containing the β-amyloid antigenic determinant peptide of SEQ ID NO:3 (hereinafter abbreviated as Aβ7) in soybean seeds was constructed.
An oligonucleotide having three copies of the nucleotide sequence encoding Aβ7 which are tandemly linked to each other (the sense strand, SEQ ID NO:68) and the oligonucleotide having its complementary sequence (the antisense strand, SEQ ID NO:69) were synthesized using the custom DNA synthesis service by FASMAC Co., Ltd. (the sense strand and the antisense strand are hereinafter referred to as 410F and 410R, respectively). Unless otherwise specified, the hereinafter-mentioned oligonucleotides were those synthesized using the custom DNA synthesis service by the above manufacturer. In the presence of ATP at a final concentration of 1 mM, 100 pmol each of 410F and 410R were subjected to phosphorylation reaction with T4 Polynucleotide Kinase (manufactured by TAKARA BIO INC.), and the resulting reaction solutions were mixed together, followed by heating at 94° C. for 10 minutes and then allowing the mixture to cool gradually to 37° C. for 1 hour, thereby carrying out annealing. By this process, a double-stranded DNA fragment encoding a peptide wherein three copies of Aβ7 are tandemly linked to each other (Aβ7×3) was obtained.
Using, as a template, the plasmid pBSK-A1aB1b, wherein cDNA of a known A1aB1b gene (GenBank accession No. AB113349) is cloned at the SmaI site of pBluescript II SK(−) (manufactured by Stratagene), PCR was carried out to amplify a fragment containing the vector portion such that the 5′-end and the 3′-end of the fragment are positioned at a specific variable region of the gene encoding A1aB1b. The obtained DNA fragment was ligated with the double-stranded DNA fragment encoding (Aβ7×3), to prepare a plasmid containing the gene encoding a modified A1aB1b. The method is more concretely described below.
A total of three primer sets for insertion into the variable regions II, III and IV of the gene encoding A1aB1b of SEQ ID NO:2, that is, the primer set (PS-1, SEQ ID NOs:70 and 71), the primer set (PS-2, SEQ ID NOs:66 and 67) and the primer set (PS-3, SEQ ID NOs:72 and 73) were prepared.
PCR was performed using 10 ng of pBSK-A1aB1b as a template. In the PCR, 50 μL/reaction of a reaction solution was used, and 2 minutes of denaturation at 94° C. and subsequent 25 cycles of 30 seconds of denaturation at 94° C., 30 seconds of annealing at 57° C. and 5 minutes of extension at 68° C. were performed. The reaction solution contained 200 μM dNTP mixture, 1.5 mM MgSO4 solution, each of the above primers at a concentration of 1 μM, and KOD-Plus-Ver.2 buffer containing 1 unit of KOD-Plus- (manufactured by Toyobo Co. Ltd.).
Using DNA Ligation Kit (manufactured by TAKARA BIO), 50 fmol of the obtained DNA fragment and 150 fmol of the double-stranded DNA fragment encoding the above-described (Aβ7×3) were subjected to ligation reaction at 16° C. for 40 minutes. The nucleotide sequence of the prepared gene encoding modified A1aB1b (hereinafter referred to as A1aB1bM1) were confirmed.
Example 13
Production of Modified Soybean Protein by E. coli 
Plasmids for expressing the thus prepared A1aB1bMK1 and A1aB1bM1 in E. coli to produce the respective proteins were constructed.
The DNA fragments of the A1aB1bMK1 and A1aB1bM1 genes obtained above were subjected to phosphorylation reaction, and ligated with a commercially available E. coli expression vector pET-21d (manufactured by NOVAGEN) which had been preliminarily cleaved with NcoI and XhoI and blunted with T4 DNA polymerase (manufactured by TAKARA BIO INC.), followed by dephosphorylation with CIAP (manufactured by TAKARA BIO INC.). By analyzing the nucleotide sequences of the obtained clones, clones in which the A1aB1bMK1 and A1aB1bM1 genes are linked in the forward direction were selected.
Thus, the E. coli expression vectors pETA1aB1bMK1 and pETA1 aB1bM1 were constructed, each of which has a 6×His tag in the downstream of the gene encoding A1aB1bMK1 or A1aB1bM1.
The commercially available E. coli strain AD494 (manufactured by NOVAGEN) was transformed with each of pETA1 aB1bMK1 and pETA1 aB1bM1 prepared by the method described above, and precultured at 37° C. at 120 rpm for 18 hours in conventional LB medium to which 15 mg/l kanamycin and 50 mg/l carbenicillin were added as antibiotics. The precultured bacterial suspension was added, in an amount of 5% (v/v), to newly prepared modified LB medium wherein 15 mg/l kanamycin and 50 mg/l carbenicillin were supplied as antibiotics and the concentration of NaCl was changed to 1M, and culture was carried out at 37° C. at 120 rpm for 2 hours, followed by adding IPTG to a final concentration of 1 mM and continuing the culture at 20° C. at 50 rpm.
Thereafter, bacterial cells were collected by centrifugation, and as a result, about 10 g of bacterial cells were collected from 6 L of the culture liquid.
From the obtained bacterial cells, the soluble protein fraction was extracted using commercially available BugBuster Protein Extraction Reagent (manufactured by NOVAGEN). The extracted proteins were purified using commercially available HisBind Purification Kits (manufactured by NOVAGEN). The purified proteins were desalted by dialysis using the buffer of 50 mM Tris-HCl (pH 8.0) containing 300 mM NaCl for one day and night.
Thus, 96 mg of pETA1 aB1bMK1 and 60 mg of pETA1aB1bM1 were obtained as modified proteins.
Example 14
Production of Modified Soybean Protein by Recombinant Soybean
To allow seed-specific expression of the gene encoding A1aB1bMK1, the gene encoding A1aB1bMK1 obtained as described above, the known soybean promoter Gy1P and terminator Gy1T were ligated with the pUHG vector (Y. Kita, K. Nishizawa, M Takahashi, M. Kitayama, M. Ishimoto. (2007) Genetic improvement of somatic embryogenesis and regeneration in soybean and transformation of the improved breeding lines. Plant Cell Reports 26:439-447), to construct an expression plasmid.
At first, in order to obtain a DNA fragment encoding A1aB1bMK1 (SEQ ID NO:74), PCR was carried out using the primer set of the oligonucleotides having the sequences shown in SEQ ID NOs:76 and 77. PCR was performed using 50 μL/reaction of a reaction solution, by carrying out 2 minutes of denaturation at 94° C. and then 25 cycles of 30 seconds of denaturation at 94° C., 30 seconds of annealing at 57° C. and 2 minutes of extension at 68° C. Thus, a DNA fragment of the A1aB1bMK1 gene was obtained. The DNA fragment of the A1aB1bMK1 gene, the promoter DNA fragment and the terminator DNA fragment were subjected to phosphorylation reaction, and then ligated with the pUHG vector that had been preliminarily digested with SmaI and dephosphorylated with CIAP (manufactured by TAKARA BIO INC.). By analyzing the nucleotide sequences of the obtained clones, clones in which the Gy1P promoter, the gene encoding A1aB1bMK1 and the Gy1T terminator are correctly linked in this order were selected. Thus, the plant transformation vector pUHGA1aB1bMK1 for expressing the gene encoding A1aB1bMK1 in a seed-specific manner was constructed.
In a similar manner, the plant transformation vector pUHGA1aB1bM1 wherein the Gy1P promoter, the gene encoding A1aB1bM1 and the Gy1T terminator are correctly linked in this order, which vector allows seed-specific expression of the gene encoding A1aB1bM1 (SEQ ID NO:78), was constructed.
These plant transformation vectors were subjected to gene transfer into soybean cells by a conventional method, and many transformed seeds wherein the A1aB1bMK1 and A1aB1bM1 proteins are expressed and accumulated in the seeds were obtained. The accumulation of the A1aB1bMK1 and A1aB1bM1 proteins in the seeds was confirmed by Western blotting using a known amyloid β antibody.
Purification of A1aB1bM1 Protein
Ten A1aB1bM1 protein-accumulating seeds (1.92 g) obtained in Example 1 were pulverized by mill and the obtained pulverized product was mixed with ten times volume of hexane and stirred with shaking for one hour at room temperature for delipidation. After removing hexane by centrifugation at 15,000 rpm at room temperature for 30 minutes, the pulverized product of seeds was air-dried. The weight after air-drying was 1.8 g. The delipidated pulverized product of seeds was mixed with 20 ml of the protein-extraction buffer composed of 0.4M NaCl, 35 mM sodium phosphate (pH7.6), 10 mM 2-mercaptoethanol, 1% protease inhibitor cocktail (Protease Inhibitor Cocktail for plant cell and tissue extracts, DM SO solution, SIGMA) and stirred with shaking for one hour at room temperature for protein extraction. 16 ml of the supernatant was recovered by centrifugation at 15,000 rpm at room temperature for 30 minutes and protein concentration was measured by RC DC Protein Assay Kit II (BioRad). The protein concentration was 16.8 mg/ml, which showed that 269 mg of seed proteins was extracted. The obtained seed protein solution was applied to gel filtration chromatography according to the following conditions.

    Column: Sephacryl S-300 26 mmID×60 cm (GE Healthcare)
    Flow rate: 2 ml/min
    Buffer: 0.4M NaCl, 35 mM sodium phosphate (pH7.6), 0.02% sodium azide, 10 mM 2-mercaptoethanol
    Fraction collection: 3 min/fraction


A1aB1bM1 fraction was determined by subjecting each fraction to western blotting in the same way as Example 4. Thereby, 48 ml of purified A1aB1bM1 solution (1 mg/ml) was collected. The purity was 100% as a result of western blotting using A1aB1bM1 protein produced by E. coli in Example 3 as a standard.
Example 15
Measurement of Anti-Amyloid β Antibody Titer in Mouse Serum after Administration of Vaccine Compositions
Using 5 individuals/test group of commercially available 2 month-old mice (BALB/c), A1aB1bMK1 and A1ab1bM1 was subcutaneously administered with a dose of 50 μg/individual 5 times at 1-week intervals. As an adjuvant, 12 μg/individual/dose of AbISCO-100 (manufactured by ISCONOVA) was used. Ten weeks after the beginning of the administration, blood was collected from the mice, and the amount of anti-Aβ42 antibody in the serum was measured. To each well of a 96-well ELISA plate (manufactured by greiner), 100 μl of a synthetic Aβ1-42 peptide (manufactured by Peptide Institute Inc.) (5 μg/mL) was adsorbed, and the well was blocked with Blocker Casein in PBS (manufactured by Thermo SCIENTIFIC). The mouse serum was added to the well, and the detection was carried out with a peroxidase enzyme-labeled anti-mouse IgG antibody (manufactured by Thermo SCIENTIFIC). As a detection reagent, 1-step Ultra TMB-ELISA (manufactured by Thermo SCIENTIFIC) was used. The antibody titer was evaluated by measurement of the absorbance (O.D. 450) using RAINBOW sunrise microplate reader (manufactured by TECAN).
The results are shown in FIG. 10. Compared to the control group (A1aB1b-administered group), all the individuals in the treated group showed a higher absorbance, and remarkable increase in the antibody titer was observed.
Example 16
Behavior Test after Oral Administration of Vaccine Composition
For the behavior test, the known Morris water maze test was carried out. Using the APP transgenic mouse TgCRND8 (Chishti M A, Yang D S, Janus C, Phinney A L, Home P, Pearson J, Strome R, Zuker N, Loukides J, French J, Turner S, Lozza G, Grilli M, Kunicki S, Morissette C, Paquette J, Gervais F, Bergeron C, Fraser P E, Carlson G A, George-Hyslop P S, Westaway D., THE JOURNAL OF BIOLOGICAL CHEMISTRY 276(24):21562-70 (2001)) of 2 months old, the effect of A1aB1bM1 on recovery of cognitive ability was studied. The mice were divided into 2 groups each of which contained 8 individuals, and pretrained. These groups were used as the A1aB1bM1-administered group, and the amyloid antigen-free A1aB1b-administered control group. In the A1aB1bM1-administered group, a total of 16 times of oral administration was carried out with a dose of 0.5 mg/individual at 1-week intervals (for 4 months). The A1aB1b-administered control group was also treated in the same manner.
The test was carried out by placing a circular platform at the bottom of a circular pool (150 cm diameter, 45 cm depth) such that the platform is submerged in water, and allowing the mice to learn the position of the platform, followed by subjecting the mice to once per day of a swimming test for 5 continuous days at intervals of 1 month. In this test, the time required for each mouse to reach the platform after the beginning of the swimming was measured.
The results are shown in FIG. 11. In the A1aB1bM1-administered group, significant improvement in the time required for reaching the platform was observed as compared to the A1aB1b-administered control group, and it was therefore revealed that administration of A1aB1bM1 improves the learning disability of the diseased mouse.
Example 17
Influence on Brain Amyloid
The transgenic mice to which A1aB1bM1 or A1aB1b was orally administered or non-administered transgenic mice were anatomized 4 months after the administration, and the cortex of the frontal lobe, parietal lobe, and the cortex of the hippocampus were fixed with 4% paraformaldehyde, followed by embedding the fixed tissues in paraffin wax, to prepare brain tissue sections. To detect the amyloid β protein or amyloid plaques using the tissues, the tissue sections were treated with 70% formic acid, and endogenous peroxidase was inactivated with 5% H2O2. Thereafter, the tissue sections were reacted with a rabbit anti-pan-Aβ antibody (1000-fold diluted), and a peroxidase-labeled secondary antibody was added thereto, followed by DAB staining. The stained sections were observed using a 3CCD camera connected to a microscope, and the area of the portion in which amyloid β is accumulated in each region was measured, to calculate the area ratio (index).
The amyloid β deposition index is shown in FIG. 12.
It was confirmed that, by the administration of A1aB1bM1, the number of amyloid plaques significantly decreased as compared to the controls.
Industrial Applicability
Since, by the present invention, it is possible to produce and accumulate an Alzheimer's disease vaccine in host such as soybean seeds as a fusion protein with a seed storage protein such as soybean 11S globulin or 7S globulin, common bean arcelin, or rice prolamin, and a large amount of the Alzheimer's disease vaccine can be produced and supplied for prophylaxis and/or therapy of Alzheimer's disease.
While the invention has been described in detail with reference to preferred embodiments thereof, it will be apparent to one skilled in the art that various changes can be made, and equivalents employed, without departing from the scope of the invention. Each of the aforementioned documents is incorporated by reference herein in its entirety.

## Claims

1. A vaccine composition for decreasing amyloid plaque formation and/or therapy of Alzheimer's disease, which comprises a fusion protein prepared by inserting tandemly repeated 2 to 5 copies of amyloid β antigenic peptide consisting of the amino acid sequence of SEQ ID NO:3 into a wild type seed storage protein, wherein said seed storage protein is AlaBlb subunit of so bean 11S globulin, and said tandemly repeated 2 to 5 copies of amyloid β antigenic peptide have been inserted into a variable region encoding the amino acid sequence corresponding to amino acid positions 198-216 of SEQ ID NO:2.

2. The vaccine composition according to claim 1, wherein said vaccine composition induces production of amyloid-specific antibodies in an animal given said vaccine composition.

3. The vaccine composition according to claim 1, wherein said vaccine composition decreases soluble and/or insoluble amyloid β1 to 42 involved in amyloid plaques in the brain of an animal suffering from Alzheimer's disease by the administration of said vaccine composition to said animal.

4. The vaccine composition according to claim 1, wherein said vaccine composition induces recovery of cognitive abilities in an animal suffering from Alzheimer's disease.

5. A method for decreasing amyloid plaque formation and/or treating Alzheimer's disease, said method comprising the step of administering a vaccine composition to an animal which has amyloid plaques in its brain, wherein said vaccine composition comprises a fusion protein prepared by inserting tandemly repeated 2 to 5 copies of amyloid β antigenic peptide consisting of the amino acid sequence of SEQ ID NO:3 into a wild type seed storage protein, wherein said seed storage protein is A1aB1b subunit of soybean 11S globulin, and said tandemly repeated 2 to 5 copies of amyloid β antigenic peptide have been inserted into a variable region encoding the amino acid sequence corresponding to amino acid positions 198-216 of SEQ ID NO:2.

6. The method according to claim 5, wherein said vaccine composition induces production of amyloid-specific antibodies in the animal given said vaccine composition.

7. The method according to claim 5, wherein said vaccine composition decreases soluble and/or insoluble amyloid β1 to 42 involved in amyloid plaques in the brain of the animal suffering from Alzheimer's disease by the administration of said vaccine composition to said animal.

8. The method according to claim 5, wherein said vaccine composition induces recovery of cognitive abilities in said animal.

9. A vaccine composition for decreasing amyloid plaque formation and/or therapy of Alzheimer's disease, which comprises a fusion protein comprising a) tandemly repeated 2 to 5 copies of amyloid β antigenic peptide consisting of the amino acid sequence of SEQ ID NO:3; and b) a wild type seed storage protein, wherein said seed storage protein is A1aB1b subunit of soybean 11S globulin, and said tandemly repeated 2 to 5 copies of amyloid βantigenic peptide have been inserted into a variable region encoding the amino acid sequence corresponding to amino acid positions 198-216 of SEQ ID NO:2.

10. A method for decreasing amyloid plaque formation and/or treating Alzheimer's disease, said method comprising the step of administering the vaccine composition of claim 9 to an animal which has amyloid plaques in its brain.

11. The method according to claim 10, wherein said vaccine composition induces production of amyloid-specific antibodies in the animal given said vaccine composition.

12. The method according to claim 10, wherein said vaccine composition decreases soluble and/or insoluble amyloid β1 to 42 involved in amyloid plaques in the brain of the animal suffering from Alzheimer's disease by the administration of said vaccine composition to said animal.

13. The method according to claim 10, wherein said vaccine composition induces recovery of cognitive abilities in said animal.

14. The vaccine composition according to claim 1, wherein said tandemly repeated 2 to 5 copies of amyloid β antigenic peptide have been inserted into additional variable regions, wherein said variable regions consist of amino acid positions 111-128 and/or amino acid positions 268-315 in wild-type SEQ ID NO: 2 prior to said modification.

15. The method according to claim 5, wherein said tandemly repeated 2 to 5 copies of amyloid β antigenic peptide have been inserted into additional variable regions, wherein said variable regions consist of amino acid positions 111-128 and/or amino acid positions 268-315 in wild-type SEQ ID NO: 2 prior to said modification.

16. The vaccine composition according to claim 9, wherein said tandemly repeated 2 to 5 copies of amyloid β antigenic peptide have been inserted into additional variable regions, wherein said variable regions consist of amino acid positions 111-128 and/or amino acid positions 268-315 in wild-type SEQ ID NO: 2 prior to said modification.